Hematopoietic Stem Cell Transplantation: Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.Hematopoietic Stem Cells: Progenitor cells from which all blood cells derive.Transplantation, Homologous: Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.Stem Cell Transplantation: The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.Transplantation Conditioning: Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.Kidney Cortex Necrosis: Death of cells in the KIDNEY CORTEX, a common final result of various renal injuries including HYPOXIA; ISCHEMIA; and drug toxicity.Dentinogenesis: The formation of dentin. Dentin first appears in the layer between the ameloblasts and odontoblasts and becomes calcified immediately. Formation progresses from the tip of the papilla over its slope to form a calcified cap becoming thicker by the apposition of new layers pulpward. A layer of uncalcified dentin intervenes between the calcified tissue and the odontoblast and its processes. (From Jablonski, Dictionary of Dentistry, 1992)Stem Cells: Relatively undifferentiated cells that retain the ability to divide and proliferate throughout postnatal life to provide progenitor cells that can differentiate into specialized cells.Peripheral Blood Stem Cell Transplantation: Transplantation of stem cells collected from the peripheral blood. It is a less invasive alternative to direct marrow harvesting of hematopoietic stem cells. Enrichment of stem cells in peripheral blood can be achieved by inducing mobilization of stem cells from the BONE MARROW.Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.Bone Marrow Transplantation: The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.Transplantation Chimera: An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.Tissue Donors: Individuals supplying living tissue, organs, cells, blood or blood components for transfer or transplantation to histocompatible recipients.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Cord Blood Stem Cell Transplantation: Transplantation of STEM CELLS collected from the fetal blood remaining in the UMBILICAL CORD and the PLACENTA after delivery. Included are the HEMATOPOIETIC STEM CELLS.Hematopoiesis: The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).Graft Survival: The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.Myeloablative Agonists: Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.Histocompatibility Testing: Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed)Whole-Body Irradiation: Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.Hematopoietic Stem Cell Mobilization: The release of stem cells from the bone marrow into the peripheral blood circulation for the purpose of leukapheresis, prior to stem cell transplantation. Hematopoietic growth factors or chemotherapeutic agents often are used to stimulate the mobilization.Busulfan: An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.Histocompatibility: The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.Antigens, CD34: Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.Chimerism: The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from different individuals. This contrasts with MOSAICISM in which the different cell populations are derived from a single individual.Graft vs Leukemia Effect: Immunological rejection of leukemia cells following bone marrow transplantation.Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Liver Transplantation: The transference of a part of or an entire liver from one human or animal to another.Recurrence: The return of a sign, symptom, or disease after a remission.Cell Differentiation: Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.Bone Marrow Cells: Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.Mesenchymal Stem Cell Transplantation: Transfer of MESENCHYMAL STEM CELLS between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS).Hematologic Diseases: Disorders of the blood and blood forming tissues.Remission Induction: Therapeutic act or process that initiates a response to a complete or partial remission level.Immunosuppressive Agents: Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.Hepatic Veno-Occlusive Disease: Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.HLA Antigens: Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.Cell Lineage: The developmental history of specific differentiated cell types as traced back to the original STEM CELLS in the embryo.Siblings: Persons or animals having at least one parent in common. (American College Dictionary, 3d ed)Unrelated Donors: Providers of tissues for transplant to non-related individuals.Vidarabine: A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.Cell Transplantation: Transference of cells within an individual, between individuals of the same species, or between individuals of different species.Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.Stem Cell Niche: A particular zone of tissue composed of a specialized microenvironment where stem cells are retained in a undifferentiated, self-renewable state.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Embryonic Stem Cells: Cells derived from the BLASTOCYST INNER CELL MASS which forms before implantation in the uterine wall. They retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells.Graft vs Tumor Effect: Immunological rejection of tumor tissue/cells following bone marrow transplantation.Adult Stem Cells: Cells with high proliferative and self renewal capacities derived from adults.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.Transplantation Immunology: A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.Severe Combined Immunodeficiency: Group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. It is inherited as an X-linked or autosomal recessive defect. Mutations occurring in many different genes cause human Severe Combined Immunodeficiency (SCID).Kidney Transplantation: The transference of a kidney from one human or animal to another.Mice, Inbred C57BLLymphocyte Transfusion: The transfer of lymphocytes from a donor to a recipient or reinfusion to the donor.Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.Fetal Blood: Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery.Transplantation, Isogeneic: Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Colony-Forming Units Assay: A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.Hazardous Substances: Elements, compounds, mixtures, or solutions that are considered severely harmful to human health and the environment. They include substances that are toxic, corrosive, flammable, or explosive.Granulocyte Colony-Stimulating Factor: A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines.Salvage Therapy: A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.Cytomegalovirus Infections: Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.Antilymphocyte Serum: Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.Anemia, Aplastic: A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements.Donor Selection: The procedure established to evaluate the health status and risk factors of the potential DONORS of biological materials. Donors are selected based on the principles that their health will not be compromised in the process, and the donated materials, such as TISSUES or organs, are safe for reuse in the recipients.Allografts: Tissues, cells, or organs transplanted between genetically different individuals of the same species.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Lymphocyte Depletion: Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation.T-Lymphocytes: Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Cells, Cultured: Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.Acute Disease: Disease having a short and relatively severe course.Graft Rejection: An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient.Cannabis: The plant genus in the Cannabaceae plant family, Urticales order, Hamamelidae subclass. The flowering tops are called many slang terms including pot, marijuana, hashish, bhang, and ganja. The stem is an important source of hemp fiber.Mesenchymal Stromal Cells: Bone-marrow-derived, non-hematopoietic cells that support HEMATOPOETIC STEM CELLS. They have also been isolated from other organs and tissues such as UMBILICAL CORD BLOOD, umbilical vein subendothelium, and WHARTON JELLY. These cells are considered to be a source of multipotent stem cells because they include subpopulations of mesenchymal stem cells.Pluripotent Stem Cells: Cells that can give rise to cells of the three different GERM LAYERS.Multipotent Stem Cells: Specialized stem cells that are committed to give rise to cells that have a particular function; examples are MYOBLASTS; MYELOID PROGENITOR CELLS; and skin stem cells. (Stem Cells: A Primer [Internet]. Bethesda (MD): National Institutes of Health (US); 2000 May [cited 2002 Apr 5]. Available from: http://www.nih.gov/news/stemcell/primer.htm)Stem Cell Factor: A hematopoietic growth factor and the ligand of the cell surface c-kit protein (PROTO-ONCOGENE PROTEINS C-KIT). It is expressed during embryogenesis and is a growth factor for a number of cell types including the MAST CELLS and the MELANOCYTES in addition to the HEMATOPOIETIC STEM CELLS.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Opportunistic Infections: An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.Immunosuppression: Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs.Immunocompromised Host: A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.Lymphoproliferative Disorders: Disorders characterized by proliferation of lymphoid tissue, general or unspecified.Organ Transplantation: Transference of an organ between individuals of the same species or between individuals of different species.Transplantation: Transference of a tissue or organ from either an alive or deceased donor, within an individual, between individuals of the same species, or between individuals of different species.Heart Transplantation: The transference of a heart from one human or animal to another.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Mice, SCID: Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.Fetal Stem Cells: Cells derived from a FETUS that retain the ability to divide, proliferate and provide progenitor cells that can differentiate into specialized cells.Minor Histocompatibility Antigens: Allelic alloantigens often responsible for weak graft rejection in cases when (major) histocompatibility has been established by standard tests. In the mouse they are coded by more than 500 genes at up to 30 minor histocompatibility loci. The most well-known minor histocompatibility antigen in mammals is the H-Y antigen.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Lung Transplantation: The transference of either one or both of the lungs from one human or animal to another.Cytarabine: A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)Neural Stem Cells: Self-renewing cells that generate the main phenotypes of the nervous system in both the embryo and adult. Neural stem cells are precursors to both NEURONS and NEUROGLIA.Infection: Invasion of the host organism by microorganisms that can cause pathological conditions or diseases.Lymphopoiesis: Formation of LYMPHOCYTES and PLASMA CELLS from the lymphoid stem cells which develop from the pluripotent HEMATOPOIETIC STEM CELLS in the BONE MARROW. These lymphoid stem cells differentiate into T-LYMPHOCYTES; B-LYMPHOCYTES; PLASMA CELLS; or NK-cells (KILLER CELLS, NATURAL) depending on the organ or tissues (LYMPHOID TISSUE) to which they migrate.Neoplasm, Residual: Remnant of a tumor or cancer after primary, potentially curative therapy. (Dr. Daniel Masys, written communication)Living Donors: Non-cadaveric providers of organs for transplant to related or non-related recipients.Fatal Outcome: Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.Cytomegalovirus: A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.Cell Culture Techniques: Methods for maintaining or growing CELLS in vitro.Hematopoietic System: The blood-making organs and tissues, principally the bone marrow and lymph nodes.Mice, Inbred NOD: A strain of non-obese diabetic mice developed in Japan that has been widely studied as a model for T-cell-dependent autoimmune insulin-dependent diabetes mellitus in which insulitis is a major histopathologic feature, and in which genetic susceptibility is strongly MHC-linked.Induced Pluripotent Stem Cells: Cells from adult organisms that have been reprogrammed into a pluripotential state similar to that of EMBRYONIC STEM CELLS.Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.MycosesAntigens, CD: Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.Stomatitis: INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.Blood Group Incompatibility: An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984).Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).Transplantation Tolerance: An induced state of non-reactivity to grafted tissue from a donor organism that would ordinarily trigger a cell-mediated or humoral immune response.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Immunophenotyping: Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.Mesonephros: One of a pair of excretory organs (mesonephroi) which grows caudally to the first pair (PRONEPHROI) during development. Mesonephroi are the permanent kidneys in adult amphibians and fish. In higher vertebrates, proneprhoi and most of mesonephroi degenerate with the appearance of metanephroi. The remaining ducts become WOLFFIAN DUCTS.Prospective Studies: Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group.Survivors: Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.Regeneration: The physiological renewal, repair, or replacement of tissue.Virus Activation: The mechanism by which latent viruses, such as genetically transmitted tumor viruses (PROVIRUSES) or PROPHAGES of lysogenic bacteria, are induced to replicate and then released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell LIPOPOLYSACCHARIDES, glucocorticoid hormones, halogenated pyrimidines, IONIZING RADIATION, ultraviolet light, and superinfecting viruses.Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).Blood Cells: The cells found in the body fluid circulating throughout the CARDIOVASCULAR SYSTEM.Platelet Transfusion: The transfer of blood platelets from a donor to a recipient or reinfusion to the donor.Antineoplastic Agents, Alkylating: A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)Etoposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.Lymphoma: A general term for various neoplastic diseases of the lymphoid tissue.Blood Cell Count: The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.Cystitis: Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.Bronchiolitis Obliterans: Inflammation of the BRONCHIOLES leading to an obstructive lung disease. Bronchioles are characterized by fibrous granulation tissue with bronchial exudates in the lumens. Clinical features include a nonproductive cough and DYSPNEA.Transplantation, Heterologous: Transplantation between animals of different species.Leukapheresis: The preparation of leukocyte concentrates with the return of red cells and leukocyte-poor plasma to the donor.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Aspergillosis: Infections with fungi of the genus ASPERGILLUS.Primary Myelofibrosis: A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.Epstein-Barr Virus Infections: Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).Lentivirus: A genus of the family RETROVIRIDAE consisting of non-oncogenic retroviruses that produce multi-organ diseases characterized by long incubation periods and persistent infection. Lentiviruses are unique in that they contain open reading frames (ORFs) between the pol and env genes and in the 3' env region. Five serogroups are recognized, reflecting the mammalian hosts with which they are associated. HIV-1 is the type species.Immunologic Deficiency Syndromes: Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.Cell Count: The number of CELLS of a specific kind, usually measured per unit volume or area of sample.Islets of Langerhans Transplantation: The transference of pancreatic islets within an individual, between individuals of the same species, or between individuals of different species.Transduction, Genetic: The transfer of bacterial DNA by phages from an infected bacterium to another bacterium. This also refers to the transfer of genes into eukaryotic cells by viruses. This naturally occurring process is routinely employed as a GENE TRANSFER TECHNIQUE.Genetic Therapy: Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions.Roseolovirus Infections: Infection with ROSEOLOVIRUS, the most common in humans being EXANTHEMA SUBITUM, a benign disease of infants and young children.Incidence: The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.Mice, Transgenic: Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.Radiation Chimera: An organism whose body contains cell populations of different genotypes as a result of the TRANSPLANTATION of donor cells after sufficient ionizing radiation to destroy the mature recipient's cells which would otherwise reject the donor cells.Proto-Oncogene Proteins c-kit: A protein-tyrosine kinase receptor that is specific for STEM CELL FACTOR. This interaction is crucial for the development of hematopoietic, gonadal, and pigment stem cells. Genetic mutations that disrupt the expression of PROTO-ONCOGENE PROTEINS C-KIT are associated with PIEBALDISM, while overexpression or constitutive activation of the c-kit protein-tyrosine kinase is associated with tumorigenesis.Thymus Gland: A single, unpaired primary lymphoid organ situated in the MEDIASTINUM, extending superiorly into the neck to the lower edge of the THYROID GLAND and inferiorly to the fourth costal cartilage. It is necessary for normal development of immunologic function early in life. By puberty, it begins to involute and much of the tissue is replaced by fat.Ganciclovir: An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections.Mice, Knockout: Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.Lymphocyte Count: The number of LYMPHOCYTES per unit volume of BLOOD.Fanconi Anemia: Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)Leukemic Infiltration: A pathologic change in leukemia in which leukemic cells permeate various organs at any stage of the disease. All types of leukemia show various degrees of infiltration, depending upon the type of leukemia. The degree of infiltration may vary from site to site. The liver and spleen are common sites of infiltration, the greatest appearing in myelocytic leukemia, but infiltration is seen also in the granulocytic and lymphocytic types. The kidney is also a common site and of the gastrointestinal system, the stomach and ileum are commonly involved. In lymphocytic leukemia the skin is often infiltrated. The central nervous system too is a common site.Pancytopenia: Deficiency of all three cell elements of the blood, erythrocytes, leukocytes and platelets.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Biological Markers: Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.Polymerase Chain Reaction: In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.Phenotype: The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.Lymphohistiocytosis, Hemophagocytic: A group of related disorders characterized by LYMPHOCYTOSIS; HISTIOCYTOSIS; and hemophagocytosis. The two major forms are familial and reactive.Fetal Tissue Transplantation: Transference of fetal tissue between individuals of the same species or between individuals of different species.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Blood DonorsDisease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Myeloid Progenitor Cells: Stem cells derived from HEMATOPOIETIC STEM CELLS. Derived from these myeloid progenitor cells are the MEGAKARYOCYTES; ERYTHROID CELLS; MYELOID CELLS; and some DENDRITIC CELLS.Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.Intervertebral Disc Chemolysis: The dissolving of the nucleus pulposus, the semi-gelatinous tissue of a displaced INTERVERTEBRAL DISC. It is usually achieved by the direct injection of a proteolytic enzyme, especially CHYMOPAPAIN, into the herniated disc.Genetic Vectors: DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.Feasibility Studies: Studies to determine the advantages or disadvantages, practicability, or capability of accomplishing a projected plan, study, or project.Retroviridae: Family of RNA viruses that infects birds and mammals and encodes the enzyme reverse transcriptase. The family contains seven genera: DELTARETROVIRUS; LENTIVIRUS; RETROVIRUSES TYPE B, MAMMALIAN; ALPHARETROVIRUS; GAMMARETROVIRUS; RETROVIRUSES TYPE D; and SPUMAVIRUS. A key feature of retrovirus biology is the synthesis of a DNA copy of the genome which is integrated into cellular DNA. After integration it is sometimes not expressed but maintained in a latent state (PROVIRUSES).Mucopolysaccharidosis I: Systemic lysosomal storage disease caused by a deficiency of alpha-L-iduronidase (IDURONIDASE) and characterized by progressive physical deterioration with urinary excretion of DERMATAN SULFATE and HEPARAN SULFATE. There are three recognized phenotypes representing a spectrum of clinical severity from severe to mild: Hurler syndrome, Hurler-Scheie syndrome and Scheie syndrome (formerly mucopolysaccharidosis V). Symptoms may include DWARFISM; hepatosplenomegaly; thick, coarse facial features with low nasal bridge; corneal clouding; cardiac complications; and noisy breathing.Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)Vincristine: An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)Pancreas Transplantation: The transference of a pancreas from one human or animal to another.Killer Cells, Natural: Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.Thrombotic Microangiopathies: Diseases that result in THROMBOSIS in MICROVASCULATURE. The two most prominent diseases are PURPURA, THROMBOTIC THROMBOCYTOPENIC; and HEMOLYTIC-UREMIC SYNDROME. Multiple etiological factors include VASCULAR ENDOTHELIAL CELL damage due to SHIGA TOXIN; FACTOR H deficiency; and aberrant VON WILLEBRAND FACTOR formation.Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)Hematology: A subspecialty of internal medicine concerned with morphology, physiology, and pathology of the blood and blood-forming tissues.Neoplastic Stem Cells: Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.Cell Survival: The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.Receptors, KIR: A family of receptors found on NK CELLS that have specificity for a variety of HLA ANTIGENS. KIR receptors contain up to three different extracellular immunoglobulin-like domains referred to as D0, D1, and D2 and play an important role in blocking NK cell activation against cells expressing the appropriate HLA antigens thus preventing cell lysis. Although they are often referred to as being inhibitory receptors, a subset of KIR receptors may also play an activating role in NK cells.Bone Marrow Purging: Techniques for the removal of subpopulations of cells (usually residual tumor cells) from the bone marrow ex vivo before it is infused. The purging is achieved by a variety of agents including pharmacologic agents, biophysical agents (laser photoirradiation or radioisotopes) and immunologic agents. Bone marrow purging is used in both autologous and allogeneic BONE MARROW TRANSPLANTATION.Multivariate Analysis: A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.Pyrimidines: A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.ABO Blood-Group System: The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane.EuropeCell- and Tissue-Based Therapy: Therapies that involve the TRANSPLANTATION of CELLS or TISSUES developed for the purpose of restoring the function of diseased or dysfunctional cells or tissues.Cell Division: The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.Bone Marrow DiseasesCohort Studies: Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics.B-Lymphocytes: Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.Stromal Cells: Connective tissue cells of an organ found in the loose connective tissue. These are most often associated with the uterine mucosa and the ovary as well as the hematopoietic system and elsewhere.HLA-A Antigens: Polymorphic class I human histocompatibility (HLA) surface antigens present on almost all nucleated cells. At least 20 antigens have been identified which are encoded by the A locus of multiple alleles on chromosome 6. They serve as targets for T-cell cytolytic responses and are involved with acceptance or rejection of tissue/organ grafts.

Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. (1/7058)

BACKGROUND: Since 1968 it has been known that bone marrow transplantation can ameliorate severe combined immunodeficiency, but data on the long-term efficacy of this treatment are limited. We prospectively studied immunologic function in 89 consecutive infants with severe combined immunodeficiency who received hematopoietic stem-cell transplants at Duke University Medical Center between May 1982 and September 1998. METHODS: Serum immunoglobulin levels and lymphocyte phenotypes and function were assessed and genetic analyses performed according to standard methods. Bone marrow was depleted of T cells by agglutination with soybean lectin and by sheep-erythrocyte rosetting before transplantation. RESULTS: Seventy-seven of the infants received T-cell-depleted, HLA-haploidentical parental marrow, and 12 received HLA-identical marrow from a related donor; 3 of the recipients of haploidentical marrow also received placental-blood transplants from unrelated donors. Except for two patients who received placental blood, none of the recipients received chemotherapy before transplantation or prophylaxis against graft-versus-host disease. Of the 89 infants, 72 (81 percent) were still alive 3 months to 16.5 years after transplantation, including all of the 12 who received HLA-identical marrow, 60 of the 77 (78 percent) who were given haploidentical marrow, and 2 of the 3 (67 percent) who received both haploidentical marrow and placental blood. T-cell function became normal within two weeks after transplantation in the patients who received unfractionated HLA-identical marrow but usually not until three to four months after transplantation in those who received T-cell-depleted marrow. At the time of the most recent evaluation, all but 4 of the 72 survivors had normal T-cell function, and all the T cells in their blood were of donor origin. B-cell function remained abnormal in many of the recipients of haploidentical marrow. In 26 children (5 recipients of HLA-identical marrow and 21 recipients of haploidentical marrow) between 2 percent and 100 percent of B cells were of donor origin. Forty-five of the 72 children were receiving intravenous immune globulin. CONCLUSIONS: Transplantation of marrow from a related donor is a life-saving and life-sustaining treatment for patients with any type of severe combined immunodeficiency, even when there is no HLA-identical donor.  (+info)

Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. (2/7058)

Intensive chemotherapy given in early chronic phase of chronic myelogenous leukemia (CML) has resulted in high numbers of circulating Philadelphia (Ph) chromosome-negative hematopoietic progenitor cells (HPC). We have autografted 30 consecutive patients with CML in chronic phase with HPC collected in this way to facilitate restoration of Ph-negative hematopoiesis in bone marrow after high-dose therapy. Hematopoietic recovery to greater than 0.5 x10(9)/L neutrophils and to greater than 25 x 10(9)/L platelets occurred in all patients, a median of 13 (range, 9 to 32) days and 16 (range, 6 to 106) days postautograft, respectively. Regenerating marrow cells were Ph-negative in 16 (53%) patients and greater than 66% Ph-negative in 10 (33%) patients. Twenty-eight patients are alive 6 to 76 months (median, 24 months) after autografting. Three patients have developed blast crisis from which 2 have died. Eight patients are in complete cytogenetic remission at a median of 20 (range, 6 to 44) months with a median ratio BCR-ABL/ABL of 0.002 (range, <0.001 to 0.01). Eight patients are in major cytogenetic remission at a median of 22 (range, 6 to 48) months. No patient died as a consequence of the treatment. All patients had some degree of stomatitis that was severe in 15 (50%) patients. Gastrointestinal and hepatic toxicities were observed in about one fourth of patients. Thus, autografting with Ph-negative mobilized HPC can result in prolonged restoration of Ph-negative hematopoiesis for some patients with CML; moreover, most autograft recipients report normal or near normal activity levels, suggesting that this procedure need not to be associated either with prolonged convalescence or with chronic debility.  (+info)

Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by Ex vivo expansion. (3/7058)

Hematopoietic reconstitution of ablated recipients requires that intravenously (IV) transplanted stem and progenitor cells "home" to organs that support their proliferation and differentiation. To examine the possible relationship between homing properties and subsequent engraftment potential, murine bone marrow (BM) cells were labeled with fluorescent PKH26 dye and injected into lethally irradiated hosts. PKH26(+) cells homing to marrow or spleen were then isolated by fluorescence-activated cell sorting and assayed for in vitro colony-forming cells (CFCs). Progenitors accumulated rapidly in the spleen, but declined to only 6% of input numbers after 24 hours. Although egress from this organ was accompanied by a simultaneous accumulation of CFCs in the BM (plateauing at 6% to 8% of input after 3 hours), spleen cells remained enriched in donor CFCs compared with marrow during this time. To determine whether this differential homing of clonogenic cells to the marrow and spleen influenced their contribution to short-term or long-term hematopoiesis in vivo, PKH26(+) cells were sorted from each organ 3 hours after transplantation and injected into lethally irradiated Ly-5 congenic mice. Cells that had homed initially to the spleen regenerated circulating leukocytes (20% of normal counts) approximately 2 weeks faster than cells that had homed to the marrow, or PKH26-labeled cells that had not been selected by a prior homing step. Both primary (17 weeks) and secondary (10 weeks) recipients of "spleen-homed" cells also contained approximately 50% higher numbers of CFCs per femur than recipients of "BM-homed" cells. To examine whether progenitor homing was altered upon ex vivo expansion, highly enriched Sca-1(+)c-kit+Lin- cells were cultured for 9 days in serum-free medium containing interleukin (IL)-6, IL-11, granulocyte colony-stimulating factor, stem cell factor, flk-2/flt3 ligand, and thrombopoietin. Expanded cells were then stained with PKH26 and assayed as above. Strikingly, CFCs generated in vitro exhibited a 10-fold reduction in homing capacity compared with fresh progenitors. These studies demonstrate that clonogenic cells with differential homing properties contribute variably to early and late hematopoiesis in vivo. The dramatic decline in the homing capacity of progenitors generated in vitro underscores critical qualitative changes that may compromise their biologic function and potential clinical utility, despite their efficient numerical expansion.  (+info)

Modulation of VLA-4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF. (4/7058)

We have evaluated the immunophenotype, functional activity and clonogenic potential of CD34+ cells from peripheral blood (PB) of normal donors before and after 4 and 6 days of G-CSF administration. The percentage and absolute number of CD34+ cells significantly increased at days 4 and 6 of G-CSF administration, compared to the steady-state level (P < 0.0001). Two-colour fluorescence analysis showed, at days 4 and 6, a lower proportion of CD34+/c-kit+ compared to the steady-state level (P < 0.0001), but a similar expression of CD13, CD33, CD38, HLA-DR and Thy-1 antigens on CD34+ cells. The expression of adhesion molecules on CD34+ cells revealed a significant reduction of CD11a (P = 0.009), CD18, CD49d and CD62L (P < 0.0001) at days 4 and 6, compared to the baseline level. Three-colour staining showed a reduction of the more immature compartment (34+/DR-/13-) and an increase of the more differentiated compartment (34+/DR+/13+). Downregulation of VLA-4 during mobilisation was seen almost exclusively on more committed cells (34+/13+); downregulation of CD62L, on the contrary, was observed on both early progenitors (34+/13-) and more committed cells (34+/13+). The expression of 34+/VLA-4+ decreased on both c-kit+ and c-kit- cells, while the expression of 34+/62L+ decreased on the c-kit+ cells only. In vivo administration of G-CSF reduced the adherence capacity of CD34+ cells to normal BM stroma; in vitro incubation with SCF or IL-3 enhanced the expression of CD49d on CD34+ cells, while GM-CSF reduced the expression of CD62L. SCF was the only cytokine able to induce a significant increase of CD34+ cell adherence to preformed stroma. Pre-incubation with the blocking beta2 integrin monoclonal antibody caused a reduction of CD34+ cell adherence. In conclusion, the decrease of CD49d expression on mobilized CD34+ cells correlates with a poor adhesion to BM stroma; CD34+ cells incubated in vitro with SCF showed, conversely, a higher expression of CD49d and a greater adherence capacity on normal preformed stroma.  (+info)

The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. (5/7058)

We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients.  (+info)

Effects of short-term administration of G-CSF (filgrastim) on bone marrow progenitor cells: analysis of serial marrow samples from normal donors. (6/7058)

To determine the effect of G-CSF administration on both the total number of CD34+ cells and the primitive CD34+ subsets in bone marrow (BM), we have analyzed BM samples serially obtained from 10 normal donors in steady-state and during G-CSF treatment. Filgrastim was administered subcutaneously at a dosage of 10 microg/kg/day (n = 7) or 10 microg/kg/12 h (n = 3) for 4 consecutive days. Peripheral blood sampling and BM aspirates were performed on day 1 (just before G-CSF administration), day 3 (after 2 days of G-CSF), and day 5 (after 4 days of G-CSF). During G-CSF administration, a significant increase in the total number of BM nucleated cells was observed. The percentage (range) of CD34+ cells decreased in BM from a median of 0.88 (0.47-1.44) on day 1 to 0.57 (0.32-1.87), and to 0.42 (0.16-0.87) on days 3 and 5, respectively. We observed a slight increase in the total number of BM CD34+ cells on day 3 (0.66 x 10(9)/l (0.13-0.77)), and a decrease on day 5 (0.23 x 10(9)/l (0.06-1.23)) as compared with steady-state (0.40 x 10(9)/l (0.06-1.68)). The proportion of primitive BM hematopoietic progenitor cells (CD34+CD38-, CD34+HLA-DR-, CD34+CD117-) decreased during G-CSF administration. In parallel, a significant increase in the total number of CD34+ cells in peripheral blood was observed, achieving the maximum value on day 5. These results suggest that in normal subjects the administration of G-CSF for 5 days may reduce the number of progenitor cells in BM, particularly the most primitive ones.  (+info)

Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. (7/7058)

The effect of an extensive prophylactic antimicrobial regimen was prospectively assessed in 126 patients after high-dose chemotherapy and autologous PBSC. They received ciprofloxacin (500 mg/12 h), acyclovir (200 mg/6 h), and itraconazole (200 mg/12 h) orally until neutrophil recovery. Febrile patients received i.v. imipenem (500 mg/6 h) to which vancomycin and amikacin were added if fever persisted for 2-3 and 5 days, respectively. Amphotericin B lipid complex was further given on day 7 or 8 of fever. Median times for a neutrophil count of >0.5 x 10(9)/l and a platelet count of >20 x 10(9)/l were 9 and 11 days. Severe neutropenia (<0.1 x 10(9)/l) lasted for a median of 5 days in which 72% of febrile episodes and 50% of cases of bacteremia occurred. Gram-positive bacteria were isolated in 30 of 40 episodes of bacteremia, 25 of which were caused by Staphylococcus epidermidis. Clinical foci were the intravascular catheter in 35 cases, respiratory infection in 11, cellulitis in two, anal abscess in one, and neutropenic enterocolitis in one. The high incidence of febrile episodes (94%) and bacteremias (31%) may be due to the lack of efficacy of antimicrobial prophylaxis and the persistence of a 5-day period of severe neutropenia.  (+info)

Immunoregulatory cytokines in bone marrow and peripheral blood stem cell products. (8/7058)

In these studies, we compared the phenotype, function, and expression of type 1, type 2, and monocyte-associated cytokine mRNA transcripts in autologous bone marrow (BM) and growth factor-mobilized peripheral blood stem cell (PSC) products. These studies demonstrate that lymphocytes and monocytes in stem cell products are abnormally activated, expressing significantly higher levels of interleukin (IL)-2, 4 and 10, interferon gamma (IFN-gamma), and tumor necrosis factor alpha (TNF-alpha), but not IL-8, as compared to normal peripheral blood mononuclear cells (PBMC). In addition, the levels of IL-2, IL-10 and TNF-alpha are significantly higher in mobilized PSC as compared to BM products. The high cytokine levels are unexpected as T cell function in stem cell products is depressed. PSC products have high levels of T cell inhibitory activity, which directly correlates with IL-10 expression, both of which are mechanisms that might be involved in the immune dysfunction within stem cell products used for autologous stem cell transplantation. These data demonstrate that: (1) immune cells in autologous BM and PSC products are activated with the expression of high levels of type 1 and type 2 cytokines as well as monokines; (2) PSC products contain a high frequency of monocytes which mediate T cell inhibitory activity; and (3) despite the high levels of cytokine expression, T cell function in stem cell products is depressed. The significance of these immune abnormalities within stem cell products for myeloid and lymphoid recovery following autologous stem cell transplantation remains to be determined.  (+info)

*Hematopoietic stem cell transplantation

... (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... Hematopoietic stem cell transplantation remains a dangerous procedure with many possible complications; it is reserved for ... December 2010). "Oral cancer in patients after hematopoietic stem-cell transplantation: long-term follow-up suggests an ... Researchers have conducted small studies using non-myeloablative hematopoietic stem cell transplantation as a possible ...

*List of conditions treated with hematopoietic stem cell transplantation

Hematopoietic stem cell transplantation may be used to treat a number of conditions both congenital and acquired. Malignancies ... "Long-Term Control of HIV by CCR5 Delta32/Delta32 Stem-Cell Transplantation". N Engl J Med. 360 (7): 692-698. doi:10.1056/ ... Immunodeficiencies T-cell deficiencies Ataxia-telangiectasia DiGeorge syndrome Combined T- and B-cell deficiencies Severe ... globoid cell leukodystrophy) Mucopolysaccharidoses Hurler syndrome (MPS I H, α-L-iduronidase deficiency) Scheie syndrome (MPS I ...

*Reticular dysgenesis

Hematopoietic Stem Cell Transplantation (HSCT) involves intravenous infusion of stem cells to those who have either a damaged ... Hematopoietic stem cells give rise to blood cells. Differentiation and proliferation of hematopoietic stem cells require a lot ... RD can only be treated temporarily through Hematopoietic stem cell transplantation (HSCT) and Cytokine Therapy. Transplantation ... "Hematopoietic Stem Cell Transplantation". Medscape. "Severe combined immunodeficiency (SCID)". Retrieved 2016-11-20. ...

*Chronic myelomonocytic leukemia

Robert J. Soiffer (17 November 2008). Hematopoietic Stem Cell Transplantation. Springer. ISBN 978-1-934115-05-3. Retrieved 23 ... Haematopoietic stem cell transplant remains the only curative treatment for CMML. However, due to the late age of onset and ... as well as abnormal looking cells (dysplasia) in at least one type of blood cell. CMML shows characteristics of a ... In adults, blood cells are formed in the bone marrow, by a process that is known as haematopoiesis. In CMML, there are ...

*Experiments in immunology

2009). "Hematopoietic Stem Cell Transplantation." Retrieved 13 Nov, 2009, from [2].. ... Another method is hematopoietic stem-cell transfer, used for studying lymphocyte development. Hematopoietic cells are killed by ... and the hematopoietic system is replaced by transfusion of donor bone marrow or purified hematopoietic stem cells. The ... Cells of interest are bound to antibody-coated plastic surfaces, and unwanted cells are removed by treatment with specific ...

*Malignant infantile osteopetrosis

PMID 28326337 Orchard PJ, Fasth AL, Le Rademacher J, et al (2015). "Hematopoietic stem cell transplantation for infantile ... The only effective line of treatment for malignant infantile osteopetrosis is hematopoietic stem cell transplantation.[citation ... have demonstrated bone remodeling and recanalization of medullar canals following hematopoietic stem cell transplantation. This ... radiographic pathology in a case of malignant infantile osteopetrosis following hematopoietic stem cell transplantation". Egypt ...

*Barrier nursing

Hematopoietic Stem Cell Transplantation in Clinical Practice. Edinburgh: Churchill Livingstone. pp. 355-361. ISBN 9780443101472 ...

*Narinder Kumar Mehra

272-. ISBN 978-93-5152-415-1. N. K. Mehra (5 July 2011). "Hematopoietic Stem Cell Transplantation : Opportunities and ... List of foreign recipients of the National Order of Merit Hematopoietic stem cell transplantation Diabetes mellitus type 1 ... He sits on the National Board of Advisors of the Center for Stem Cell Science, and the Advisory Board of Indus Foundation and ... "National Board of Advisors". Center for Stem Cell Science. 2017. "Advisory Board". Indus Foundation. 2017. "Board of Immunology ...

*Autoimmune enteropathy

Hematopoietic stem cell transplantation may be curative. ^ Montalto, M; D'Onofrio, F; Santoro, L; Gallo, A; Gasbarrini, A; ... This test is done to look at the stomach and small intestines and to see what cells are infiltrating the digestive tract. There ...

*Total body irradiation

The number of pregnancies observed after hematopoietic stem cell transplantation involving such as procedure is lower than 2%. ... Tichelli André, Rovó Alicia (2013). "Fertility Issues Following Hematopoietic Stem Cell Transplantation". Expert Rev Hematol. 6 ... is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell (or bone marrow) ... preventing immunologic rejection of transplanted donor bone marrow or blood stem cells. Additionally, high doses of total body ...

*Female infertility

Tichelli André; Rovó Alicia (2013). "Fertility Issues Following Hematopoietic Stem Cell Transplantation". Expert Rev Hematol. 6 ... Tichelli André; Rovó Alicia (2013). "Fertility Issues Following Hematopoietic Stem Cell Transplantation". Expert Rev Hematol. 6 ... and the number of pregnancies observed after hematopoietic stem cell transplantation involving such as procedure is lower than ... Fat cells produce estrogen, in addition to the primary sex organs. Too much body fat causes production of too much estrogen and ...

*Stem cell marker

March 1997). "Factors predicting morbidity following hematopoietic stem cell transplantation". Bone Marrow Transplantation. 19 ... Stem cell markers are genes and their protein products used by scientists to isolate and identify stem cells. Stem cells can ... 2005). "Somatic stem cell marker prominin-1/CD133 is expressed in embryonic stem cell-derived progenitors". Stem Cells. 23 (6 ... Hirao A, Arai F, Suda T (December 2004). "Regulation of cell cycle in hematopoietic stem cells by the niche". Cell Cycle. 3 (12 ...

*Central pontine myelinolysis

It has been observed following hematopoietic stem cell transplantation. CPM may also occur in patients prone to hyponatraemia ... "Central pontine myelinolysis in a patient with acute lymphoblastic leukemia after hematopoietic stem cell transplantation: a ... When the correction is too rapid, not enough time is allowed for the brain's cells to adjust to the new tonicity, namely by ... The reverse is true in hypernatremia, in which the cells increase their intracellular osmolytes so as not to lose too much ...

*Fanconi anemia

2013). "Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the EBMT experience". Blood. 122: 4279-4286. doi: ... A more permanent cure is hematopoietic stem cell transplantation. If no potential donors exist, a savior sibling can be ... although more recent published evidence suggests that earlier allogeneic hematopoietic progenitor cell transplantation in ... "Role of Fanconi DNA repair pathway in neural stem cell homeostasis". Cell Cycle. 7 (13): 1911-5. doi:10.4161/cc.7.13.6235. PMID ...

*Leukocyte adhesion deficiency

"Allogeneic hematopoietic stem cell transplantation for Leukocyte Adhesion Deficiency". Pediatrics. 123 (3): 836-840. doi: ... the only current curative therapy is the hematopoietic stem cell transplant. However, progress has been made in gene therapy, ... A 2009 study reported results from 36 children who had received a stem cell transplant. At the time of follow-up (median time ... Cell. 50 (2): 193-202. doi:10.1016/0092-8674(87)90215-7. PMID 3594570. van Vliet DN, Brandsma AE, Hartwig NG (2004). "Leukocyte ...

*Neuronal ceroid lipofuscinosis

Oct 2001). "Hematopoietic stem cell transplantation in infantile neuronal ceroid lipofuscinosis". Neurology. 57 (8): 1411-6. ... The therapy is being developed by Stem Cells Inc and is estimated to have six patients. The treatment will be carried out in ... On October 20, 2005, the Food and Drug Administration approved a phase I clinical trial of neural stem cells to treat infantile ... Juvenile NCL has recently been listed on the Federal Clinical Trials website to test the effectiveness of bone marrow/stem cell ...

*Valine

"Depleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation". Science. 354 (6316): 1152- ... Successful stem cell transplantation was achieved in mice without irradiation after 3 weeks on a valine restricted diet. Long ... Dietary valine is essential for hematopoietic stem cell (HSC) self-renewal, as demonstrated by experiments in mice. Dietary ... In sickle-cell disease, a single glutamic acid in β-globin is replaced with valine. Because valine is hydrophobic, whereas ...

*Donor lymphocyte infusion

Loren AW, Porter DL (2006). "Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation". Current ... or buffy coat infusion is a form of adoptive immunotherapy used after hematopoietic stem cell transplantation. Formerly, the ... Thomas' Hematopoietic Cell Transplantation, ed. Blume KG, Forman SJ, Appelbaum FR. Blackwell Publishers, Cambridge, MA: 2004. ... These donated white blood cells contain cells of the immune system that can recognize and destroy cancer cells. The goal of ...

*Bone marrow suppression

Hematopoietic stem cell transplantation Neutropenia, low leukocytes "bone marrow suppression". Retrieved 3 May 2011. ... Unlike chemotherapy the affects may not be due to direct destruction of stem cells but the results may be equally serious. The ... The decrease in blood cell counts does not occur right at the start of chemotherapy because the drugs do not destroy the cells ... In-vitro colony forming cell (CFC) assays using normal human bone marrow grown in appropriate semi-solid media such as ...

*Sahara Hospital

The hospital started a hematopoietic stem cell transplantation programme in 2011. Among other specialty services are cardiology ...

*Thalassemia

Gaziev, J; Lucarelli, G (June 2011). "Hematopoietic stem cell transplantation for thalassemia". Current Stem Cell Research & ... 2011). "T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients". Pediatric reports. 3 ( ... "Hematopoietic stem cell transplantation for people with ß-thalassaemia major". The Cochrane Database of Systematic Reviews. 11 ... Thalassemia is often accompanied by the destruction of a large number of red blood cells and the task of removing these cells ...

*Andrew Pecora

2003-11-15). "Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma". Blood. ... 1998). "CD34+CD33- cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients". ... March 2000). "Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy". Journal of Clinical ... to become assistant director of stem cell and bone marrow transplantation from 1990 to 1993. He went on to become the program's ...

*Transplantable organs and tissues

Hematopoietic stem cell transplantation (HSCT) is the transplantation of blood stem cells derived from the bone marrow (that is ... With the availability of the stem cell growth factors GM-CSF and G-CSF, most hematopoietic stem cell transplantation procedures ... Stem cell transplantation was pioneered using bone-marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research ... Cutler C, Antin JH (2001). "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. ...

*Management of Crohn's disease

2005). "Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease". Gastroenterology. 128 ... Autologous stem cell transplants have also been evaluated. Rifabutin, clarithromycin and clofazimine are antibiotics designed ... Garg, M. Jones, R. M., Vaughan, R. B., Testro, A. G. (2011). Intestinal transplantation: Current status and future directions. ... They are purine anti-metabolites, meaning that they interfere with the synthesis of purines required for inflammatory cells. ...

*Alvin J. Siteman Cancer Center

The new technique would later be called autologous hematopoietic stem cell transplantation. Mid-1970s - Imaging Michel Ter- ... 2011 - Blood-related cancers Siteman completes its 5,000th hematopoietic stem cell transplantation, a common therapy for ... Washington University School of Medicine and UC San Diego School of Medicine shows that the virus kills brain cancer stem cells ... Highlights and ongoing studies include these projects: 2017 - CAR-T cell therapy and using Zika virus to fight brain cancer In ...

*CD34

... are used to quantify and purify hematopoietic progenitor stem cells for research and for clinical bone marrow transplantation. ... It is important to mention that Long-Term Hematopoietic Stem Cells (LT-HSCs) in mice and humans are the hematopoietic cells ... in a cell surface glycoprotein and functions as a cell-cell adhesion factor. It may also mediate the attachment of stem cells ... CD34+ cell) are normally found in the umbilical cord and bone marrow as hematopoietic cells, or in mesenchymal stem cells, ...
OBJECTIVE: To explore the outcome of human leukocyte antigen (HLA)-mismatched/haploidentical hematopoietic stem cell transplantation (HSCT) for refractory/relapsed acute leukemia (AL) patients and its related risk factors.. METHODS: 96 refractory/relapsed AL patients who received HLA-mismatched/haploidentical HSCT following conditioning regimen comprised of modified busulfan/cyclophosphamide (BU/CY) plus thymoglobulin (ATG) from Jan 2003 to Jun 2011 were analyzed retrospectively.. RESULTS: Of the 96 patients, 61 suffered from acute myeloid leukemia (AML), and 35 acute lymphoid leukemia (ALL), all of them in non-remission (NR) or relapse before transplantation. With a median follow-up of 373 (34 - 3157) d, 33 cases (34%) survived, 31 survived without leukemia, and 35 relapsed. The estimated 3-year overall survival (OS) and disease-free survival (DFS) rate was 30.2% and 29.0%, respectively. The 3-year OS rate was significantly higher for AML patients (39.2%) than for ALL patients (15.4%) (P = ...
Геморрагический энтерит, ассоциированный с парвовирусом В19 после трансплантации гемопоэтических стволовых клеток: клинический случай и данные литературыHaemorrhagic enteritis associated with parvovirus B19 following hematopoietic stem cell transplantation: a case report and literature data
A nosocomial pneumonia caused by Legionella pneumophilaserogroup 2oc-14oc curred in a 7-year-old patient following allogeneic hematopoietic stem cell transplantation for thalassemia major. The patient was diagnosed as nosocomial Legionella pneumonia by a polymerase chain reaction (PCR) from bronchoalveolar lavage and a culture of L. pneumophilaserogroup 2-14 from patients room faucet water. Legionella was eradicated from our hospitals water distribution system by superheating and chemical eradication methods (hyper-chlorination and hydrogen peroxide). We did not detect any case after this event. Early recognition of contamination of hospital water system with Leigonella proves the importance of prevention new cases. ...
A 60-year-old man presented with impaired consciousness and psychomotor agitation after a second allogeneic haematopoietic stem cell transplantation (HSCT) from a matched unrelated donor for acute myeloid leukaemia. Clinical, biological and radiological evidence suggested a diagnosis of central nervous system graft-versus-host disease (CNS-GvHD). After intrathecal infusion of methylprednisolone, the clinical symptoms as well as the radiological abnormalities disappeared. The present report illustrates the difficulties in the diagnosis and the management of CNS-GvHD, a very rare and still challenging neurological complication that can occur after allogeneic HSCT. ...
Purpose of reviewCytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic haematopoietic stem cell transplantation (HSCT). CMV surveillance-preemptive therapy is the current preferred approach for preventing CMV disease after HSCT. In contrast, antiviral prophylaxis is no
TY - JOUR. T1 - Respiratory virus infections in pediatric hematopoietic stem cell transplantation. AU - Luján-Zilbermann, Jorge. AU - Benaim, Ely. AU - Tong, Xin. AU - Srivastava, Deo K.. AU - Patrick, Christian C.. AU - Devincenzo, John. PY - 2001/10/1. Y1 - 2001/10/1. N2 - Respiratory virus infections (RVI) have become an increasingly appreciated problem in the hematopoietic stem cell transplant (HSCT) population. A retrospective analysis of 274 patients undergoing 281 HSCT at St. Jude Childrens Research Hospital from January 1994 through December 1997 was performed. Medical and clinical laboratory records were reviewed beginning at the onset of conditioning through the year following each HSCT, and the analysis was done for the first RVI only. Thirty-two (11%) of 281 HSCT cases developed a RVI during the first year post-HSCT. The most frequent cause of RVI was human parainfluenza virus type 3. Univariate analysis was performed to determine the association between risk factors and the ...
TY - JOUR. T1 - Rapid immune reconstitution following autologous hematopoietic stem cell transplantation in children. T2 - A single institution experience. AU - Hoepfner, S.. AU - Haut, Paul. AU - OGorman, M.. AU - Kletzel, M.. PY - 2003/2. Y1 - 2003/2. N2 - In this retrospective study, we review the immune reconstitution of children undergoing autologous hematopoietic stem cell transplantation. A total of 125 patients underwent autologous transplantation between 1992 and 2000. The report includes data on 58 patients. Data were not available on the remaining patients who either died before testing or data were not obtained. The parameters evaluated include: (a) immunophenotype by flow cytometry to quantify lymphocyte subpopulations (b) mitogen stimulation assays, and (c) quantitative immunoglobulins. The analysis reveals that CD3+ cells did not reach the normal range during the first year post-transplant. The median percentage of CD4 + cells was below normal up to 6 months post-transplant, ...
Background. Haploidentical hematopoietic stem-cell transplantation (haplo-HSCT) is associated with an increased risk of graft failure and severe graft-versus-host disease (GVHD). Marrow mesenchymal stromal cells (MSCs) have been shown to support in vivo normal hematopoiesis and to display potent immunosuppressive effects. We launched a multi-center clinical study to examine the safety and feasibility of co-transplantation of MSCs (from third party donors) and haploidentical HSCs into 35 children with severe aplastic anemia (SAA). Methods. A total of 35 children with SAA were enrolled in this multi-center study between January 2014 and December 2016. All patients met the criteria of HLA-mismatched with ⩾5/10 HLA-matched loci. The conditioning regimen for haploidentical hematopoietic stem cell transplantation consisted of busulfan (Bu), cyclophosphamide and ATG. BM and peripheral blood CD34+ cells were infused intravenously ⩾5×108 cells/kg and ⩾2×106 cells/kg of recipient weight on day 01 ...
According to a recently published report by Brisk Insights, the Global Hematopoietic Stem Cells Transplantation Market is expected to grow at the CAGR of 10.4 % during 2017-2025. The global hematopoietic stem cells transplantation market is segmented on the basis of application, transplant type, and geography. The report on global hematopoietic stem cells transplantation market (by application, transplant type, and geography) provides a detailed overview and predictive analysis of the market.. Full report available on Hematopoietic Stem Cells Transplantation Market: Global Industry Size, Growth, Share and Forecast to 2025 report at http://www.briskinsights.com/report/hematopoietic-stem-cells-transplantation-market. Market Insights. Increasing prevalence of cancer and anemia in both developed and developing nations are the key growth factors in the hematopoietic stem cells transplantation market. In base year 2016, lymphoproliferative disorders and leukemia accounted for more than 50% of the ...
TY - JOUR. T1 - Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. AU - Muller, William J.. AU - Levin, Myron J.. AU - Shin, Young Kyoo. AU - Robinson, Christine. AU - Quinones, Ralph. AU - Malcolm, Janet. AU - Hild, Elaine. AU - Gao, Dexiang. AU - Giller, Roger. PY - 2005/12/15. Y1 - 2005/12/15. N2 - Post-hematopoietic stem cell transplantation (HSCT) adenovirus infections were identified in 31 of 204 consecutive pediatric HSCT patients, 18 of whom had severe manifestations of infection. Cidofovir treatment led to clinical improvement in 8 of 10 patients with severe infection and to virologic clearance in 9 patients. In vitro susceptibility to cidofovir was demonstrated in 12 clinical adenovirus isolates. Cidofovir is a promising treatment option for this population.. AB - Post-hematopoietic stem cell transplantation (HSCT) adenovirus infections were identified in 31 of 204 consecutive pediatric HSCT ...
TY - JOUR. T1 - Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. AU - Busca, Alessandro. AU - Locatelli, F.. AU - Barbui, A.. AU - Ghisetti, V.. AU - Cirillo, D.. AU - Serra, R.. AU - Audisio, E.. AU - Falda, M.. PY - 2003/9. Y1 - 2003/9. N2 - Nonmyeloablative hematopoietic stem cell transplantation (NST) has been explored in hematological malignancies and solid tumors in an attempt to minimize treatment-related toxicity. Whether this approach is associated with reduced risk of infectious complications is unclear. The aim of the current study was to evaluate the infectious complications in a series of 32 consecutive adult patients who received NSTat our institution. Peripheral blood stem cell grafts (n = 30) or marrow grafts (n = 2) were infused from human leukocyte antibody (HLA)·matched sibling (n = 30), partially matched related (n = 1), or unrelated (n = 1) donors. Neutropenia developed in two-thirds of patients and lasted 16 days. ...
Introduction. Cyclosporin (CSA) is commonly used as graft vs host disease (GvHD) prophylaxis in allogeneic haematopoietic stem cell transplant (alloHSCT) recipients. The usual IV dose is 3mg/kg and the recommended oral dose at switching is 3mg/kg BD in the pre-posaconazole era (Inoue et al. 2014). Posaconazole is now commonly used as antifungal prophylaxis in this context; it increases CSA levels through inhibition of the cytochrome involved in CSA metabolism (Sánchez-Ortega et al. 2012). We evaluated CSA-related toxicity after switch from IV to oral CSA in alloHSCT recipients receiving posaconazole with the aim of defining the optimal weight based oral dose.. Methods. A retrospective audit was performed of adult alloHSCT patients between October 2015 and October 2017 who received IV and then oral CSA together with posaconazole prophylaxis. Posaconazole was commenced during conditioning and continued at 300mg IV or oral daily according to gastrointestinal tolerance; patients with levels below ...
TY - JOUR. T1 - Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. AU - Lupo-Stanghellini, Maria Teresa. AU - Provasi, Elena. AU - Bondanza, Attilio. AU - Ciceri, Fabio. AU - Bordignon, Claudio. AU - Bonini, Chiara. PY - 2010/3/1. Y1 - 2010/3/1. N2 - Allogeneic hematopoietic stem cell transplantation (allo-SCT) from an HLA-matched related or unrelated donor is a curative option for patients with high-risk hematological diseases. In the absence of a matched donor, patients have been offered investigational transplantation strategies such as umbilical cord blood SCT or family haploidentical SCT. Besides the activity of the conditioning regimen, most of the antileukemic potential of allo-SCT relies on alloreactivity, promoted by donor lymphocytes reacting against patient-specific antigens, such as minor and major histocompatibility antigens, ultimately translating into cancer immunotherapy. Unfortunately, alloreactivity is also responsible for the most ...
Rationale: Chemotherapy with fludarabine, cyclophosphamide and anti-thymocyte globulin may induce the engraftment cross the immunologic barrier in the setting of HLA-haploidentical allogeneic hematopoietic cell transplantation. In addition, depletion CD3±CD19 cells may contribute to prevent developing severe acute graft versus host disease (GVHD) in haploidentical transplantation.. Purpose: This phase I/II trial is to evaluate the safety and efficacy of fludarabine, cyclophosphamide and antithymocyte globulin with CD3±CD19 depleted graft from haploidentical donors in treating patients with aplastic anemia. ...
EV Morozova, YuYu Vlasova, MV Barabanshchikova, NN Mamaev, IM Barkhatov, AL Alyanskii, EI Darskaya, MV Vladovskaya, SN Bondarenko, IS Moiseev, BV Afanasyev RM Gorbacheva Scientific Research Institute of Pediatric Oncology, Hematology and Transplantation; IP Pavlov First Saint Petersburg State Medical University, 6/8 Lva Tolstogo str., Saint Petersburg, Russian Federation, 197022 For correspondence: Elena Vladislavovna Morozova, MD, PhD, 6/8 Lva Tolstogo str., Saint Petersburg, Russian Federation, 197022; e-mail: [email protected] For citation: Morozova EV, Vlasova YuYu, Barabanshchikova MV, et al. Chronic Myeloid Leukemia: Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Era of Tyrosine Kinase Inhibitors. Clinical oncohematology. 2020;13(2):193-8 (In Russ). DOI: 10.21320/2500-2139-2020-13-2-193-198 ABSTRACT Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a radical method of chronic myeloid leukemia (CML) treatment. In the 1990s CML became the most frequent
TY - JOUR. T1 - Baseline profiles of ocular surface and tear dynamics after allogeneic hematopoietic stem cell transplantation in patients with or without chronic GVHD-related dry eye. AU - Wang, Y.. AU - Ogawa, Y.. AU - Dogru, M.. AU - Tatematsu, Y.. AU - Uchino, M.. AU - Kamoi, M.. AU - Okada, N.. AU - Okamoto, S.. AU - Tsubota, K.. PY - 2010/6/1. Y1 - 2010/6/1. N2 - We evaluated ocular surface alterations in allogeneic hematopoietic stem cell transplantation (HSCT) recipients with or without chronic GVHD-related dry eye in a prospective study. Fifty eyes of 25 post-HSCT patients and 28 eyes of 14 age-matched healthy controls were included. Meibomian gland (MG) obstruction, tear evaporation rate, corneal sensitivity (CS), Schirmer test-I, tear break-up time (BUT) and ocular surface vital staining were examined. Conjunctival impression and brush cytology specimens were collected to evaluate the goblet cell density (GCD) and the inflammatory cell numbers. Obvious MG obstruction, decreased CS and ...
TY - JOUR. T1 - Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation. AU - Saburi, Masuho. AU - Kohashi, Sumiko. AU - Kato, Jun. AU - Koda, Yuya. AU - Sakurai, Masatoshi. AU - Toyama, Takaaki. AU - Kikuchi, Taku. AU - Karigane, Daiki. AU - Yuda, Sayako. AU - Yamane, Yusuke. AU - Hashida, Risa. AU - Abe, Ryohei. AU - Nakazato, Tomonori. AU - Hirahashi, Junichi. AU - Ogata, Masao. AU - Okamoto, Shinichiro. AU - Mori, Takehiko. PY - 2017/5/17. Y1 - 2017/5/17. N2 - Calcineurin inhibitors (CIs) such as cyclosporine A (CSA) and tacrolimus often cause renal dysfunction, resulting in increased serum creatinine, hyperkalemia, and hyperuricemia. However, the effects of CIs on sodium excretion have not been fully elucidated. We retrospectively evaluated the effects of CI administration on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). Fifty consecutive recipients each of allogeneic HSCT ...
Historically, unmanipulated T-cell-replete haploSCT grafts with conventional graft-versus-host-disease (GVHD) prophylaxis used in the late 1970s were associated with intense bidirectional alloreactivity and unacceptably high morbidity and mortality rates due to hyperacute GVHD and graft rejection (4,5,6). This led in the 1980s to the development of complete ex vivo depletion of T cells using CD34-selected grafts. Complete T-cell depletion has been associated with a lower incidence of acute GVHD (aGVHD); however, this caused delayed immune recovery and was associated with a high nonrelapse mortality (NRM) from infections and higher disease relapse rates given the decreased graft-versus-leukemia effect, as well as a higher rate of graft rejection (7,8,9). While graft rejection was partially overcome with "megadoses" of CD34 cells (typically >107 CD34+ cells/kg) and a myeloablative conditioning regimen (including total-body irradiation [TBI], cyclophosphamide, thiotepa) with severe T-cell depletion ...
Highly diverse bacterial populations inhabit the gastrointestinal tract and modulate host inflammation and promote immune tolerance. In allogeneic hematopoietic stem cell transplantation (allo-HSCT), the gastrointestinal mucosa is damaged, and colonizing bacteria are impacted, leading to an impaired intestinal microbiota with reduced diversity. We examined the impact of intestinal diversity on subsequent mortality outcomes following transplantation. Fecal specimens were collected from 80 recipients of allo-HSCT at the time of stem cell engraftment. Bacterial 16S rRNA gene sequences were characterized, and microbial diversity was estimated using the inverse Simpson index. Subjects were classified into high, intermediate, and low diversity groups, and assessed for differences in outcomes. Mortality outcomes were significantly worse in patients with lower intestinal diversity; overall survival at three years was 36%, 60%, and 67% for low, intermediate, and high diversity groups, respectively ...
BACKGROUND & OBJECTIVE: Patients with refractory or relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation had a poor prognosis with high death rate due to relapse or transplant-related mortality (TRM). The purpose of this paper was to clarify the role of inducing acute graft-versus-host disease (aGVHD) during transplantation in preventing relapse.. METHODS: Thirty adult patients with refractory or relapsed leukemia were acute lymphoblastic leukemia (n=16), acute myelogenous leukemia (n=10), and acute mixed leukemia (n=4). They were in first complete remission (n=4), second complete remission (n=9), partly remission (n=12), and non-response (n=5) at the time of transplantation. Patients underwent allogeneic peripheral blood stem cell transplantation (allo-PBSCT) from HLA-identical siblings (n=21), mismatched siblings donors (n=3), and allogeneic bone marrow transplantation (n=5) or allo-PBSCT (n=1) from unrelated HLA matched donors. All patients received myeloablative ...
Natural Killer (NK) cells are lymphocytes of innate immunity that respond to virus infected and tumor cells. After allogeneic transplantation, NK cells are the first reconstituting lymphocytes, but are dysfunctional. Manipulating this first wave of lymphocytes could be instrumental in reducing the 40% relapse rate following transplantation with reduced intensity conditioning. NK cells express numerous activating and inhibitory receptors. Some recognize classical or non-classical HLA class I ligands, others recognize class I-like ligands or unrelated ligands. Dominant in the NK cell transplant literature are killer cell immunoglobulin-like receptors (KIR), encoded on chromosome 19q. Inhibitory KIR recognition of cognate HLA class I ligand is responsible for NK cell education, which makes them tolerant of healthy cells, but responsive to unhealthy cells having reduced expression of HLA class I. KIR A and KIR B are functionally distinctive KIR haplotype groups that differ in KIR gene content. ...
We use cookies to ensure that we give you the best experience on our website. If you click Continue well assume that you are happy to receive all cookies and you wont see this message again. Click Find out more for information on how to change your cookie settings ...
TY - JOUR. T1 - The Complex Needs of Pediatric Hematopoietic Stem Cell Donors and Their Families. T2 - Challenges and Opportunities. AU - Derrington, Sabrina F.. AU - Essner, Bonnie S.. PY - 2016/11/1. Y1 - 2016/11/1. KW - health-related quality of life. KW - palliative care. KW - resilience. KW - siblings. UR - http://www.scopus.com/inward/record.url?scp=84994479686&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84994479686&partnerID=8YFLogxK. U2 - 10.1016/j.jpeds.2016.08.052. DO - 10.1016/j.jpeds.2016.08.052. M3 - Editorial. VL - 178. SP - 14. EP - 15. JO - Journal of Pediatrics. JF - Journal of Pediatrics. SN - 0022-3476. ER - ...
The global Hematopoietic Stem Cells Transplantation (HSCT) Market is one amongst the enormously classified markets. The global Hematopoietic Stem Cells Transplantation (HSCT) market report offers information related to import and export, along with the current business chain in the market at the global level. It also delivers a plan regarding the expansion of supply and demand of the generated products and offering services compared with the key market players Kite Pharma, Thermo Fisher Scientific, CellGenix Technologie Transfer, Cesca Therapeutics, R&D Systems of the Hematopoietic Stem Cells Transplantation (HSCT) market globally.. Apply here for the sample copy of the report @: https://www.reportsbuzz.com/request-for-sample.html?repid=71502. A deep investigation of the Hematopoietic Stem Cells Transplantation (HSCT) market depends on global patterns, which have been recently incorporated into the study, is also included in the report. Furthermore, The report presents a detailed segmentation ...
The latest market report published by Credence Research, Inc. "Global Hematopoietic Stem Cells Transplantation Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2022," the hematopoietic stem cells transplantation market was valued at USD 3,741.3 Mn in 2015, and is expected to reach USD 7,796.1 Mn by 2022, expanding at a CAGR of 10.6% from 2016 to 2022.. Market Insights. Over 50 years of studies in the field of blood-forming stem cells i.e. hematopoietic stem cells (HSC), researchers have developed significant understanding to use HSCs as a therapy. At present, no type of stem cell, adult, embryonic or fetal has attained such sufficient status. Hematopoietic stem cell transplantation (HSCT) is now routinely used for treating patients with malignant and non-malignant disorders of blood and the immune system. Currently, researchers have observed that through animal studies HSCs have the ability to form other cells such as blood vessels, muscles, and bone. Further ...
This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor. The stem cells will be derived from a 1) matched unrelated donor (MUD) or 2) unrelated umbilical cord blood (UCB). Patients will receive a novel conditioning regimen with Busulfan, Cytoxan and Fludarabine (Bu/Cy/Flu) and either Alemtuzumab (Campath 1H) for recipients of a MUD or rabbit Antithymocyte Globulin (rATG) for recipients of unrelated UCB prior to hematopoietic stem cell transplant (HSCT).. It is hypothesized that reduced dosages of Cytoxan will decrease the acute toxicities associated with the standard chemotherapies of Busulfan and Cytoxan (i.e. sinusoidal obstructive syndrome (SOS), hemorrhagic cystitis and mucositis). And the addition of fludarabine to a conditioning regimen with myeloablative doses of Busulfan and reduced dosages of Cytoxan prior to HSCT will overcome the engraftment barrier posed ...
Extramedullary relapse of AML following allogeneic HSCT remains a poorly understood post-HSCT outcome. The incidence of extramedullary relapse in this study (10%) is consistent with previously reported rates over the past 35 years despite many changes in allogeneic HSCT practices.21,22 Although it is possible that patients with risk factors for extramedullary relapse are currently more likely to undergo allogeneic HSCT than they were in the past, it is more likely that the stable incidence reflects a lack of progress in this scenario. In this series of patients, we confirmed that the increased risk of extramedullary relapse for most previously reported risk factors, including pre-HSCT extramedullary disease, FAB M4/M5 AML, and advanced disease status, also apply to the post-HSCT setting.10,20 We did not, however, find there was an increased risk associated with CD56 or T-cell marker expression. While not surprising, our finding that patients with advanced disease status or high risk cytogenetics ...
Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease is a life-threatening complication following hematopoietic stem cell transplantation. A quantitative polymerase chain reaction to evaluate EBV-genome copy numbers based on a nested polymerase chain reaction and an end-point dilution was used. Applying this assay EBV load was prospectively screened weekly in 123 patients after transplantation. The results demonstrate that EBV reactivations with more than 1,000 EBV-genome copies measured in 10(5) peripheral blood mononuclear cells were observed in 31 patients (25.2%). Three patients developed lymphoproliferative disease with extremely high EBV-genome copies in peripheral blood mononuclear cells (,100,000 copies/10(5) cells) and plasma. After combined antiviral and immune therapy two of three patients showed a dramatic decrease of EBV load and survived, while the third patient died of lymphoma. A subclinical EBV reactivation was observed in 24 cases (19.5%) with ...
BACKGROUND: Allogeneic stem cell transplantation is usually considered the only curative treatment option for patients with advanced or transformed myelodysplastic syndromes in complete remission, but post-remission chemotherapy and autologous stem cell transplantation are potential alternatives, especially in patients over 45 years old. DESIGN AND METHODS: We evaluated, after intensive anti-leukemic remission-induction chemotherapy, the impact of the availability of an HLA-identical sibling donor on an intention-to treat basis. Additionally, all patients without a sibling donor in complete remission after the first consolidation course were randomized to either autologous peripheral blood stem cell transplantation or a second consolidation course consisting of high-dose cytarabine. RESULTS:
Fanconi anemia is a rare and heterogeneous inherited disorder. The natural history of FA is characterized by marrow failure and a risk for clonal evolution. Evolution to acute myeloid leukemia is the main cause of premature mortality. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) is considered the treatment of choice in this situation but the evolution is usually poor post-HSCT (due to treatment-related mortality). From August 2006 to December 2011, 6 consecutive patients with FA who received a sequential treatment with chemotherapy and reduced-intensity conditioning for clonal evolution in four different French institutions were reviewed. Five patients presented an AML and one a myelodysplastic syndrome. The sequential strategy consisted of a pre-transplant chemotherapy by fludarabine 30 mg/m2/d 5 days and cytarabine 1gr/m2x2/d 5 days with granulocyte-colony stimulating factor injections (FLAG) followed early after by a reduced-intensity conditioning [4 days cyclophosphamide 10 ...
We recently reported that adult acute myeloid leukemia (AML) patients with granulocytic sarcoma (GS) possessed unique clinical features and poor prognosis. However, the optimal therapeutic strategy for this entity has not been established. Therefore, the aim of this study was to assess the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the management of AML with GS. We retrospectively analyzed 503 consecutive adult AML patients (median age, 44 years; range, 15-73 years) who received allo-HSCT. A total of 44 patients (8.7%) had GS before transplantation. Patients with GS achieved comparable survival to those without GS (5-year overall survival (OS), 47% vs 44%, respectively, P=0.621). In patients with GS, excellent outcomes were seen in those that underwent allo-HSCT while in complete remission, whereas nine out of ten patients with GS at the time of transplant experienced a relapse within 6 months after allo-HSCT. Local irradiation for GS prior to allo-HSCT and acute and
TY - JOUR. T1 - Vitamin D level after allogeneic hematopoietic stem cell transplant. AU - Sproat, Lisa. AU - Bolwell, Brian. AU - Rybicki, Lisa. AU - Dean, Robert. AU - Sobecks, Ronald. AU - Pohlman, Brad. AU - Andresen, Steven. AU - Sweetenham, John. AU - Copelan, Edward. AU - Kalaycio, Matt. PY - 2011/7. Y1 - 2011/7. N2 - Vitamin D (VD) deficiency can cause osteomalacia, bone pain, muscle weakness, fatigue, and increased risk of fracture, and may precipitate or exacerbate osteopenia and osteoporosis. Patients receiving treatment for acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) may have limited exposure to sunlight and often experience gastrointestinal side effects that may decrease their ability to maintain an adequate VD level. We hypothesized that patients with AML and ALL would have a low VD level after allogeneic hematopoietic cell transplant (HCT), and that these patients would have a high incidence of osteoporosis/osteopenia. We therefore studied the incidence of ...
Respiratory virus infections (RVI) have become an increasingly appreciated problem in the hematopoietic stem cell transplant (HSCT) population. A retrospective analysis of 274 patients undergoing 281 HSCT at St. Jude Childrens Research Hospital from January 1994 through December 1997 was performed. Medical and clinical laboratory records were reviewed beginning at the onset of conditioning through the year following each HSCT, and the analysis was done for the first RVI only. Thirty-two (11%) of 281 HSCT cases developed a RVI during the first year post-HSCT. The most frequent cause of RVI was human parainfluenza virus type 3. Univariate analysis was performed to determine the association between risk factors and the cumulative incidence of RVI. Respiratory viruses are frequent causes of infections in the first year post-HSCT in the pediatric population. Only allogeneic transplant and the degree of acute or chronic graft versus host disease were found to be statistically significant risk factors ...
TY - JOUR. T1 - Hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia and Down syndrome. AU - Goto, Hiroaki. AU - Kaneko, Takashi. AU - Shioda, Yoko. AU - Kajiwara, Michiko. AU - Sakashita, Kazuo. AU - Kitoh, Toshiyuki. AU - Hayakawa, Akira. AU - Miki, Mizuka. AU - Kato, Keisuke. AU - Ogawa, Atsushi. AU - Hashii, Yoshiko. AU - Inukai, Takeshi. AU - Kato, Chiaki. AU - Sakamaki, Hisashi. AU - Yabe, Hiromasa. AU - Suzuki, Ritsuro. AU - Kato, Koji. PY - 2015/1/1. Y1 - 2015/1/1. N2 - Background: Hematopoietic stem cell transplantation (HSCT) is one curable option for high-risk acute lymphoblastic leukemia (ALL); however, transplant-related toxicities might be severe in patients with Down syndrome and ALL (DS-ALL). Procedure: HSCTs performed in patients with DS-ALL were identified in the Japan Society for Hematopoietic Cell Transplantation registry. Results: In the registry data, 11 patients with DS-ALL were identified. The median age at HSCT was 9 years (range: 6-22 ...
TY - JOUR. T1 - Complications and risks in hematopoietic stem cell transplant patients.. AU - Smith, L. A.. AU - Wright-Kanuth, M. S.. PY - 2001/3. Y1 - 2001/3. N2 - Hematopoietic stem cell transplantation is a recognized treatment for hematological diseases such as leukemia and lymphoma, certain solid organ tumors, and a limited number of immunologic disorders. The major risks associated with this procedure are infections and development of graft-vs-host disease. Bacterial or viral agents are the most common cause of infections, but fungal and protozoan organisms may also be isolated. Bacterial infections occur most frequently in the first 30 days after transplant, whereas the onset of viral infections usually occurs later during the first three months posttransplant. Studies have demonstrated that there are a variety of predisposing factors that influence the type of infection a patient develops. These include underlying disease, type of chemotherapy regimen, type of antimicrobial and ...
Ringden, O.; Labopin, M.; Schmid, C.; Sadeghi, B.; Polge, E.; Tischer, J.; Ganser, A.; Michallet, M.; Kanz, L.; Schwerdtfeger, R.; Nagler, A.; Mohty, M. (2016): Sequential chemotherapy followed by reduced intensity conditioning and allogeneic hematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukemia (AML): a survey from the Acute Leukemia Working Party of EBMT. In: Bone Marrow Transplantation, Vol. 51: S476-S477 ...
36th Annual Meeting of the European Group for Blood and Marrow Transplantat/9th Meeting of the EBMT Data Management Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Quality Management ...
TREOSULFAN-BASED CONDITIONING REGIMEN IN SIBLING AND ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH SICKLE CELL DISEASE
Pediatric patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) often receive intravenous liposomal amphotericin B (L-AmB) as antifungal prophylaxis. There are no guidelines for antifungal prophylaxis in children in this situation. Caspofungin (CAS), a broad-spectrum echinocandin, could be an effective alternative with lower nephrotoxicity than L-AmB. We retrospectively analyzed the safety, feasibility, and efficacy of CAS in our center, and compared the results with L-AmB as antifungal monoprophylaxis in pediatric patients undergoing HSCT. 60 pediatric patients received L-AmB (1 or 3 mg/kg bw/day) and another 60 patients received CAS (50 mg/m2/day) as antifungal monoprophylaxis starting on day one after HSCT. The median ages of patients receiving L-AmB and CAS were 7.5 years and 9.5 years, respectively. No proven breakthrough fungal infection occurred in either group during the median treatment period of 23 days in the L-AmB group and 24 days in the CAS group. One patient
Abstract: To evaluate the role of BAL, CTB, and OLB in the management of pulmonary infiltrates in pediatric HSCT recipients, we conducted a retrospective review of clinical records of pediatric HSCT recipients. Data were analyzed using Chi-square for dichotomous and anova for continuous variables. Logistic regression was used to adjust confounding variables for diagnostic yield. Forty patients underwent 44 separate procedures. Infections were the prevailing cause of infiltrates with a positive diagnostic yield (96%). CTB and OLB were performed more often in patients with focal infiltrates compared with BAL (100%, 71% vs. 22%; p , 0.01). Adverse events were not significantly different across the three procedures. OLB more often yielded information that led to change in medical management (71% vs. 0%, 34%; p , 0.05) compared with CTB and BAL. Patients who had a positive diagnostic yield had no apparent survival advantage when compared with those in whom a procedure yielded no information. Logistic ...
Antifungal Prophylaxis with Posaconazole in Allogeneic Hematopoietic Stem Cell Transplantation Using Sirolimus for Prevention of Graft-Versus-Host DiseaseConference abstracts...
TY - JOUR. T1 - Maternal perspectives on childrens health-related quality of life during the first year after pediatric hematopoietic stem cell transplant. AU - Parsons, Susan K.. AU - Shih, Mei Chiung. AU - DuHamel, Katherine N.. AU - Ostroff, Jamie. AU - Mayer, Deborah K.. AU - Austin, Jane. AU - Martini, D. Richard. AU - Williams, Sharon E.. AU - Mee, Laura. AU - Sexson, Sandra Griffin Bishop. AU - Kaplan, Sherrie H.. AU - Redd, William H.. AU - Manne, Sharon. PY - 2006/11/1. Y1 - 2006/11/1. N2 - Objective: To assess the longitudinal health-related quality of life (HRQL) of children receiving hematopoietic stem cell transplantation (HSCT). Methods: Mothers (N = 160) of HSCT recipients aged 5-20 at six US transplant centers completed the Child Health Ratings Inventories (CHRIs), the Disease Impairment Inventory (DSII)-HSCT module, and the Short Form (SF)-36 at baseline, 3, 6, and 12 months. Results: HRQL domain scores at baseline varied by recipient age and program site. Longitudinal data ...
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELOID NEOPLASMS (t-MN) OF THE ADULT: MONOCENTRIC OBSERVATIONAL STUDY AND REVIEW OF THE LITERATURE.
Xu, L.,Zhu, H. L.,Hu, J. D.,et al. SUPERIORITY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION TO NILOTINIB & DASATINIB FOR ADULT PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA IN THE ACCELERATED PHASE[J]. HAEMATOLOGICA,2015,suppl.1:434-434 ...
Allogeneic haematopoietic stem cell transplantation remains the only curative treatment of myelofibrosis with myeloid metaplasia (MMM). Previous reports have indicated significant treatment-related mortality (TRM) for patients transplanted after myeloablative conditioning but superior survival has been reported after reduced-intensity conditioning (RIC). We report the results of a survey of all allogeneic transplantations for MMM performed in Sweden at six transplant units between 1982 and 2004. Twenty-seven patients were transplanted, 17 with a myeloablative conditioning regimen and 10 with RIC. The median age was 50 years (5-63 years) at transplantation. After a median follow up of 55 months, 20 patients are alive. TRM was 10% in the RIC group and 30% in the myeloablative group. There was no difference in survival for high or low-risk patients according to Cervantes score or between sibling and unrelated donor transplantations. © 2006 The Authors.. ...
Full text of Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation : Models in Discovery and Translation 1st ed. (2013) Gerard Socie and B.R. Blazar is part of the ScienceDirect eBook Collection. For USC users only. Requires USC network connection.. ...
H&O How common is CMV infection among patients undergoing allogeneic hematopoietic stem cell transplant?. MB Cytomegalovirus (CMV) reactivation occurs in approximately 50% to 70% of seropositive patients undergoing allogeneic transplant. The rate varies depending on the diagnostic method that is used to identify reactivation. Among settings in which the donor is seropositive and the recipient is negative, the incidence is 20% to 25% (Figure).. H&O What risk factors have been identified for CMV reactivation and the development of CMV infection?. MB The CMV serostatus is important, with CMV seropositivity of the recipient being the highest-risk setting. CMV donor serostatus can affect the severity of CMV infection among seropositive recipients. However, even if both the donor and the recipient are seronegative and "CMV-safe" blood is used, CMV infection occurs in approximately 1% of patients. The conditioning regimen, including T-cell depletion, can affect the risk of reactivation, the viral load ...
The term chimerism in the setting of hematopoietic stem cell transplantation refers to the engraftment or presence of lymphohematopoietic cells of donor origin, typically detected by using techniques of DNA analysis (18). Mixed chimerism, in contrast to full donor chimerism, indicates the presence of both donor and recipient lymphohematopoietic cells. Because mixed versus total donor chimerism can now be reliably generated with specific NST regimens and avoided with other NST regimens, investigators must address an important question: is the state of mixed chimerism after transplantation desirable?. There are at least 3 theoretical advantages of mixed chimerism over full chimerism as an approach to transplantation tolerance (19), as follows: 1) mixed chimerism can be achieved with nonmyeloablative regimens that are less toxic, 2) mixed chimeras have better immune function, and 3) thymic deletion of host-reactive cells occurs to a greater degree in mixed chimeras due to the intrathymic presence ...
Background: Allogeneic Haematopoietic stem cell transplant (HSCT) is a potentially curative treatment for haematological cancers however it is a particularly aggressive treatment that can impact individuals quality of life (QOL) in multiple ways. Due to the toxicity of the transplant, adults aged over fifty years have only recently become eligible for this treatment following the development of a reduced intensity regimen. As a result, little is known regarding the experience of QOL among recipients aged over fifty years. QOL information is an essential part of assessing the success of medical treatments and can help prepare recipients for any ways in which their lives and those of their families may be impacted post-transplant. Method Potential participants were recruited through the Beatson West of Scotland Cancer Centre (BWSCC) and a purposive sample of eight participants volunteered to take part in the study. A qualitative approach, Interpretative Phenomenological Analysis was used to ...
Tissue antigens, 2007; 69 Suppl 1 doi:10.1111/j.1399-0039.2006.759_4.x. Authors: Shaw B E, Gooley T, Madrigal J A, Malkki M, Marsh S G E Shaw B E, Gooley T, Madrigal J A, Malkki M, Marsh S G E, Petersdorf E W et al.(1) Affiliation: Nottingham City Hospital, Nottingham, United Kingdom Abstract: There is increasing evidence for a significant effect of human leukocyte antigen (HLA)-DPB1 mismatching on complications following unrelated donor haematopoietic cell transplantation (HCT). In this analysis of 5930 patient/donor pairs, we found that a DPB1 mismatch predicted significantly for an increased risk of acute graft-vs-host disease [hazard ratio (HR): 1.33; P-value ...
The search strategy had the broad aim of the retrieval of all relevant studies. With respect to historical versions of the Cochrane Review,10 we applied two different search strategies and retrieved the same studies with aggregate data but different studies with individual cases data. These results show the substantial difficulty associated with the aim of searching for all published cases. This enterprise appears almost impossible. We adopted the new WHO 2013 classification of STS and made minor modifications to define a clear terminology for the study selection process. The group of NRSTS consists of many subtypes that are difficult to diagnose and separate even today. A considerable number of tumours cannot be clearly assigned to a specific histological category. Thus, we may have tumours with a specific label that might not be true. Otherwise, we may have tumours without a specific label that might belong to a specific category. We excluded studies if the proportion of non-eligible ...
TY - JOUR. T1 - Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation. AU - Shetty, Avinash K.. AU - Winter, Mary A.. PY - 2012/9/26. Y1 - 2012/9/26. N2 - In the past 3 decades, the number of immunocompromised children has increased steadily because of dramatic improvement in survival rates in certain malignancies as a result of intensive curative treatment regimens and an increase in the number of children undergoing life-saving hematopoietic stem cell transplantation (HSCT). Children receiving immunosuppressive therapy for cancer, as well as HSCT recipients, will benefit from vaccination but warrant close evaluation for a variety of reasons, such as the risk of developing severe infections, serious adverse events following certain vaccines, and decreased vaccine efficacy caused by poor immune response to vaccination. Various professional organizations have published vaccination guidelines for immunocompromised patients. Given their ...
Hematopoietic stem cell transplantation (HSCT) is an established treatment for a variety of malignant diseases, as well as a small proportion of non-malignant disorders. The treatment before the HSCT (called conditioning) can be either myeloablative (MAC) or given with reduced intensity (RIC). MAC is associated with high toxicity due to high doses of chemotherapy with or without total body irradiation (TBI), and is used in both autologous and allogeneic HSCT. In autologous HSCT the patient is the donor, and in allogeneic HSCT the donor is a sibling or an unrelated donor. RIC regimens are associated with reduced toxicity and are only for patients undergoing allogeneic HSCT. Both autologous and allogeneic HSCT have a strong effect on the patients health-related quality of life (HRQL). The two studies in this thesis were initiated when RIC was introduced at a hematological department in south-east Sweden in 2001. The overall purpose was to evaluate HRQL in patients undergoing HSCT. The studies ...
TY - JOUR. T1 - Physical therapy pathway and protocol for patients undergoing hematopoietic stem cell transplantation. T2 - Recommendations from The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group. AU - Mohammed, Jaleel. AU - Aljurf, Mahmoud. AU - Althumayri, Abdulaziz. AU - Almansour, Muntaha. AU - Alghamdi, Ahmed. AU - Hamidieh, Amir Ali. AU - ElHaddad, Alaa. AU - Othman, Tarek Ben. AU - Bazarbachi, Ali. AU - Almohareb, Fahad. AU - Alzahrani, Mohsen. AU - alkindi, salam. AU - Alsharif, Fahad. AU - Dana, Waleed. AU - Alhashmi, Hani. AU - Bekadja, Mohamed A.. AU - Al-Shammari, Salem H.. AU - El Quessar, Asma. AU - Satti, Tariq M.. AU - Aljohani, Naif. AU - Rasheed, Walid. AU - Ghavamzadeh, Ardeshir. AU - Chaudhri, Naeem. AU - Hashmi, Shahrukh K.. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Background: Patients undergoing hematopoietic stem cell transplantation (HSCT) are often referred for physical therapy (PT) to help improve their quality of life. However, to our knowledge there ...
The programmed death-1 (PD-1) pathway serves as a checkpoint to limit T-cell mediated immune responses. Blocking the PD-1 receptor on T cells with monoclonal anti-bodies results in T-cell activation and proliferation and can induce a potent immuno-therapeutic antitumour effect.
Press Release issued Jan 19, 2017: The Global Pipeline Drugs for Hematopoietic Stem Cell Transplantation Market 2017 Industry Research Report is a in-depth study and professional analysis on the current state of the Pipeline Drugs for Hematopoietic Stem Cell Transplantation market.
Background: Renal dysfunction after allogeneic hematopoietic stem cell transplantation (HSCT) has been increasingly reported. However, there are few reports on the changes of the estimated glomerular filtration rate (eGFR) in long-term survivors after allogeneic HSCT. Patients and methods: The medical records at Seoul St. Marys Hospital in Korea were reviewed to identify all adult (, 18 years of age) patients who had undergone high-dose chemotherapy and allogeneic HSCT between January 2001 and December 2005. Among these patients, those with , 5 years of follow-up and relapse within 5 years after HSCT were excluded. 85 patients were enrolled. Results: The mean follow-up was 76.0 +/- 13.5 months. The eGFR recorded 3 months after HSCT was significantly decreased compared with the eGFR recorded before HSCT. Subsequently, early decreased eGFR was maintained during the 60 months after HSCT. Multivariate analysis showed that acute kidney injury (AKI) during HSCT, hypertension (HTN) and eGFR before ...
Results The median Inflammatory Neuropathy Cause and Treatment (INCAT) score within 1 month prior to AHSCT was 6 and the Rankin score 4. Total INCAT and Rankin scores improved significantly within 2-6 months after AHSCT and continued to do so at last follow-up. The motor action potential amplitudes (CMAP) improved already within 4 months (median) after AHSCT. Three of the 11 patients relapsed during the follow-up period, requiring retransplantation with AHSCT in one. Eight of the 11 patients maintained drug-free remission upon last follow-up. AHSCT was safe but on the short term associated with a risk of cytomegalovirus (CMV) and Epstein-Barr virus reactivation, CMV disease, haemorrhagic cystitis and pancreatitis.. ...
RESULTS: In the screening of thrombophilia, 8 patients (9%) were heterozygous for factor V Leiden, 5 (6%) were homozygous for MTHFR 677TT, 12 (14%) were homozygous for MTHFR 1298CC, and 2 (2%) were heterozygous for prothrombin G20210A mutation. We observed VTE in 5 patients (5.4%); a prothrombotic risk factor was found in 3 out of these 5 patients, while 4 out of 5 patients had central venous catheters. It was determined there was no significant relationship between VTE and inherited prothrombotic risk factors ...
Although the impact of donor graft composition on clinical outcomes after hematopoietic stem cell transplantation (HSCT) has been studied, little is known about the role of intragraft γδ TCR repertoire on clinical outcomes following HSCT. Using a high-throughput sequencing platform, we sought to analyze the TCR γ-chain (TRG) repertoire of γδ T cells within donor stem cell grafts and address its potential impact on clinical response in the corresponding patients. A total of 20 peripheral blood stem cell grafts were analyzed, and donors were classified as CMV+/- The respective acute myeloid leukemia recipients were followed for disease relapse and acute graft-versus-host disease (aGvHD) development post-HSCT. In all samples, TRG repertoire showed a reduced diversity and displayed overrepresented clones. This was more prominent in grafts from CMV+ donors, which presented a more private repertoire, lower diversity, skewed distribution, and reduced usage of the V9-JP pairing. Grafts given to ...
Approaches for haploidentical bone marrow transplantation (BMT) without T-cell depletion have been designed using new transplant strategies, including anti-thymocyte globulin (ATG) preparative regimens, granulocyte colony-stimulating factor-primed grafts, post-transplantation rapamycin, or high-dose cyclophosphamide (Cy) in combination with other immunosuppressive agents for graft-versus-host disease (GVHD) prophylaxis. These strategies ensured fast hematologic engraftment across the human leukocyte antigen (HLA) barrier with an acceptable incidence of GVHD. Long-term follow-up results from different transplant centers suggest that unmanipulated transplantation may provide an alternative strategy in the haploidentical setting without requiring the technical expertise and cost of ex vivo T-cell depletion. This review discusses immune reconstitution and factors associated with clinical outcomes following unmanipulated haploidentical hematopoietic stem cell transplantation (HSCT), and compares ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
TY - JOUR. T1 - Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome. AU - Muramatsu, Hideki. AU - Sakaguchi, Hirotoshi. AU - Taga, Takashi. AU - Tabuchi, Ken. AU - Adachi, Souichi. AU - Inoue, Masami. AU - Kitoh, Toshiyuki. AU - Suminoe, Aiko. AU - Yabe, Hiromasa. AU - Azuma, Eichi. AU - Shioda, Yoko. AU - Ogawa, Atsushi. AU - Kinoshita, Akitoshi. AU - Kigasawa, Hisato. AU - Osugi, Yuko. AU - Koike, Kazutoshi. AU - Kawa, Keisei. AU - Kato, Koji. AU - Atsuta, Yoshiko. AU - Kudo, Kazuko. PY - 2014/5. Y1 - 2014/5. N2 - Allogeneic hematopoietic stem cell transplantation (HSCT) has not been widely used in patients with acute myeloid leukemia (AML) and Down syndrome (DS) due to fear of transplantation-related toxicity. A retrospective analysis of the outcome of allogeneic HSCT was conducted in 15 patients with AML and DS. The five patients transplanted with the reduced intensity conditioning (4 in complete remission (CR) and 1 in non-CR) had a ...
90751 avhandlingar från svenska högskolor och universitet. Avhandling: Anti-tumour effect in solid tumours, tolerance and immune reconstition after allogeneic haematopoietic stem cell transplantation.
Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is still the only curative treatment for Chronic Myelogenous Leukemia (CML) at present. For only few patients having suitably matched donor, transplantations with stem cells from HLA mismatched related family donors have been increasingly used. But Used of HLA mismatched HCT involves crossing histocompatibility barriers, it has been limited by high risk of severe graft-versus-host disease (GVHD), graft rejection and delayed or incomplete immune reconstruction. The inducing immune tolerance and modulate allogeneic reaction may play a role in avoiding severe GVHD in HLA-mismatched HSCT. Our goal in this study was to investigate the feasibility and clinical value of this approach in the treatment of CML. From February 1999 to February 2008, 55 patients with CML, aged 8 to 52 years (median age 29 years), received HSCT from HLA two or three loci mismatched donor, 18 were in chronic phase, 19 were in accelerated phase, 18 were in blast ...
These experiments explored mechanisms of control of acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation using a murine model of MHC-matched, minor histocompatibility antigen mismatched transplantation. The central hypothesis examined was that addition of active vaccination against leukemia cells would substantially increase the effectiveness of allogeneic donor lymphocyte infusion against ALL present in the host after transplant. While vaccination did increase the magnitude of type I T cell responses against leukemia cells associated with donor lymphocyte infusion, it did not lead to substantial improvement in long term survival. Analysis of immunological mechanisms of leukemia progression demonstrated that the failure of vaccination was not due to antigen loss in leukemia cells. However, analysis of survival provided surprising findings that, in addition to very modest type I T cell responses, a B cell response that produced antibodies that bind leukemia ...
See study data on outcomes associated with TDT patients undergoing allogeneic HSCT, and learn about potential transplant-related risk factors.
Amsterdam, The Netherlands, September 11, 2013 Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that the five year follow-up of patients with high-risk malignancies from its Phase I/II clinical study confirms long-term safety and efficacy of ATIR over a broad dose range. ATIR is a cell-based product designed to enable stem cell transplantations from partially mismatched (haploidentical) family donors for patients who do not have a standard of care stem cell donor available. The results demonstrate proof of concept and show that ATIR infusion after a T-cell depleted haploidentical hematopoietic stem cell transplantation (HSCT) provides immune protection shortly after the transplantation and improves long-term outcome in high-risk patients with very poor prognosis.. Not only does the study confirm that ATIR provides an effective treatment for patients for whom a standard of care stem cell donor is not available, the long term ...
Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy Olga Blau, Igor Wolfgang Blau Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany Abstract: Myelodysplastic syndrome (MDS) is a heterogeneous group of myeloid disorders. MDS remains a disease of elderly patients; moreover, the incidence of high risk MDS is proportionally greater in elderly patients, with increased frequency of secondary acute myeloid leukemia, as well as adverse cytogenetic abnormalities. Allogeneic stem cell transplantation is a therapeutic approach with known curative potential for patients with MDS that allows the achievement of long-term disease control. Numerous controversies still exist regarding transplantation in MDS: timing of transplantation, disease status at transplantation and comorbidity, conditioning intensity, pretransplant therapy, and stem cell source. Various transplant
Rabbit polyclonal to Dynamin-1.Dynamins represent one of the subfamilies of GTP-binding proteins.These proteins share considerable sequence similarity over the N-terminal portion of the molecule, which contains the GTPase domain.Dynamins are associated with microtubules.. black individuals from the prior research had been lost to check out up. Three brand-new alloHSCT recipients had been enrolled. We contacted five entitled alloHSCT recipients to sign up the three brand-new alloHSCT SDZ 220-581 Ammonium salt individuals. HSCT and matched-control individuals had been enrolled more than a 15-month period. The matched-control and alloHSCT characteristics are summarized in Desk 1. All individuals had been Caucasian. AlloHSCT was connected with postponed maturation. Elevation Z-scores had been markedly low in alloHSCT individuals while BMI Z-scores didnt differ considerably. AlloHSCT sitting elevation relative to elevation was considerably lower in comparison to handles (p ...
Lymphocyte reconstitution following non-myeloablative hematopoietic stem cell transplantation follows two patterns depending on age and donor/recipient chimerism.
Update on Paroxysmal Nocturnal Hemoglobinuria (PNH) Long Term Safety Study Shows 100% Transfusion Independence Two-part pivotal Phase III study of nomacopan in pediatric.
TY - JOUR. T1 - How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?. AU - Verma, A.. AU - Pedicano, J.. AU - Trifilio, S.. AU - Singhal, S.. AU - Tallman, M.. AU - Winter, J.. AU - Williams, S.. AU - Gordon, L.. AU - Monreal, J.. AU - Mehta, J.. PY - 2004/4/1. Y1 - 2004/4/1. N2 - Growth factors are routinely used after autotransplantation to accelerate hematopoietic recovery, and are continued until the absolute neutrophil count (ANC) is ≥0.5 × 109/l on 3 consecutive days. Since ANC often increases to very high levels with this strategy, we discontinued growth factor on the first day ANC reached 0.5 × 109/l in 45 patients (Study Group), and compared their subsequent ANC to 108 historic controls who received growth factor longer. While ANC on the day after reaching 0.5 × 109/l was comparable between groups, ANC on the third day was significantly higher in the Control Group (2.3 vs 4.9 × 109/l; P = ...
Rehabilitation after haematopoietic stem cell transplantation Rehabilitation nach hämatopoetischer Stammzelltransplantation The medical perspective Dr.med.Dipl.Psych. A. Mumm Director: Prof.Dr.med. H.H.
Allogeneic hematopoietic cell transplant (HCT) recipients are at increased risk for a variety of infections based upon their degree of immunosuppression and exposures. Autologous HCT recipients are also at increased risk for infection, although to a
Baker KS, Davies SM, Majhail NS, Hassebroek A, Klein JP, Ballen KK, Bigelow CL, Frangoul HA, Hardy CL, Bredeson C et al.. 2009. Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(12):1543-54. Abstract ...
This trial will evaluate the efficacy and the safety of a strategy of allogeneic stem cell transplantation including Rituximab in the conditioning regim
TY - JOUR. T1 - Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders. AU - Madden, Lisa M.. AU - Hayashi, Robert J.. AU - Chan, Ka Wah. AU - Pulsipher, Michael A.. AU - Douglas, Dorothea. AU - Hale, Gregory A.. AU - Chaudhury, Sonali. AU - Haut, Paul. AU - Kasow, Kimberly A.. AU - Gilman, Andrew L.. AU - Murray, Lisa M.. AU - Shenoy, Shalini. PY - 2016/8/1. Y1 - 2016/8/1. N2 - Reduced-intensity conditioning (RIC) before hematopoietic stem cell transplantation (HCT) in children could result in fewer complications during follow-up compared with myeloablative regimens. Hence, many RIC regimens are under investigation, but long-term follow-up is essential. We describe late follow-up beyond 2 years post-HCT in 43 children with nonmalignant disorders who underwent related or unrelated donor (56%) HCT on a multicenter study using a RIC regimen (alemtuzumab, fludarabine, and melphalan) followed by bone marrow (n = 30), peripheral ...
Allogeneic stem cell transplantation (SCT) is the only treatment with curative potential for myelodysplastic syndrome (MDS). The availability of SCT has been expanded with the introduction of reduced intensity conditioning for older patients and the use of alternative donors. Treatment-related mortality and relapse have remained major barriers to uniform success and there is a significant need for innovative approaches to improve these outcomes.
Results from a randomized, double-blind, placebo-controlled trial show that letermovir protects from viral infection in CMV-seropositive individuals following allogeneic hematopoietic cell transplantation.
in Clinical Cancer Research : An Official Journal of the American Association for Cancer Research (2003), 9(15), 5566-72. PURPOSE: Previous trials of recombinant human erythropoietin (rHuEpo) therapy after autologous hematopoietic stem cell transplantation have administered very high doses of i.v. rHuEpo starting on day 1 ... [more ▼]. PURPOSE: Previous trials of recombinant human erythropoietin (rHuEpo) therapy after autologous hematopoietic stem cell transplantation have administered very high doses of i.v. rHuEpo starting on day 1 and continuing for 1-2 months until erythroid engraftment and have shown no benefit of rHuEpo therapy. We sought to establish a more effective use of rHuEpo in this setting. EXPERIMENTAL DESIGN: In this report, we show in a first cohort of 45 lymphoma or myeloma patients undergoing peripheral blood stem cell transplant (control group) that endogenous erythropoietin levels are high for the degree of anemia during the first 3 weeks after transplant but become ...
Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood [Internet.] 2014 [cited Feb 21, 2019]; 124(3):344-53. Available from: http://www.bloodjournal.org/content/124/3/344?sso-checked=true Merskey H, Bogduk N. Part III: pain terms, a current list with definitions and notes on usage. In: Classification of chronic pain. Seattle: IASP Press; 2012. p.209-14. Gurunathan A, Patel NS, Freedman JL. Mucositis and pain in the peri-HSCT period. In: Brown VI. Hematopoietic stem cell transplantation for the pediatric hematologist/oncologist. Philadelphia: Springer; 2018. p.209-14. World Health Organization. WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. Geneva: World Health Organization; 2012. Rodrigues HF, Garbin LM, Castanho LEC, Simões BP, Curcioli ACJV, Silveira RCCP. Cateter de Hickman no transplante de células-tronco hematopoéticas: implante cirúrgico, retirada e assistência de ...
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for patients with relapsed acute myeloid leukemia. In this retrospective, multicenter study, we analyzed the outcome of 63 children (median age, 7 y; range, 0.2 to 17) who received unmanipulated allo-HSCT in second complete remission. Either a matched family donor or an unrelated donor was used in 29 (46%) and 34 (54%) patients, respectively. The stem cell source was bone marrow in 53 children (84%), peripheral blood in 7 (11%), and cord blood in 3 patients (5%). Preparative regimen included total body irradiation in 25 patients (40%). The 5-year estimates of overall survival and leukemia-free survival were 53% [95% confidence interval (CI) 39-66] and 49% (95% CI 35-63), respectively, whereas the cumulative incidence of relapse and transplant-related mortality (TRM) were 26% (95% CI 16-41) and 25% (95% CI 15-40), respectively. In multivariate analysis, the use of a matched family donor predicted a better ...
Abstract. Background: Hematopoietic stem cell transplantation (HSCT) recipients are at increased risk for infection. This study describes bone and joint infections (BJI) among HSCT recipients.. Methods: We reviewed 5861 patients who underwent HSCT at Mayo Clinic, Rochester, MN from January 1, 2005 through January 1, 2015 for study inclusion. BJI was defined as native septic arthritis, prosthetic joint infection, osteomyelitis, and orthopedic implant infection. All adults with BJI after HSCT were included in the analysis.. Results: Of 5861 patients, 33 (0.6%) developed BJI. Native joint septic arthritis was the most common BJI occurring in 15/33 (45.4%) patients. Patients were predominantly male (24/33, 72.7%), with median age of 58 (range 20-72) years. BJI was diagnosed a median of 39 (range 1-114) months after allogeneic (14/33, 42.4%) or autologous (19/33, 57.6%) HSCT. Organisms were recovered via tissue (24/27, 88.9%), synovial fluid (13/17, 76.5%), and/or blood cultures (16/25, 64%). Most ...
Despite the curative potential of allogeneic stem cell transplantation (allo-SCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), many patients will relapse. Until...
Kiadis Pharma is focused on cell-based immunotherapy products, as an adjunctive to a haploidentical hematopoietic stem cell transplantation (HSCT), for the treatment of blood cancers and inherited blood disorders. The Companys product candidates have the potential to make allogeneic HSCT safer and more effective for patients.. Based on the positive results from the single dose Phase II trial with lead product ATIR101™ in patients with blood cancer, the Company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in April 2017, for approval of ATIR101™ across the European Union as an adjunctive treatment in HSCT for malignant disease. In addition, Kiadis Pharma has received regulatory approval in various countries to start dosing patients in a Phase III trial with ATIR101™ that will be performed across Europe and North America. ATIR101™ has been granted Orphan Drug Designations both in the US and Europe.. The Companys second product candidate, ...
Purpose: Hematopoietic cell transplantation (HCT) recipients are vulnerable to invasive infection due to Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae (Sp). Evaluation of immune responses after vaccination is important to ensure protection in these immunocompromised hosts. Data on antibody response after vaccination against Hib and Sp are needed in Korean HCT recipients. Materials and Method: Pediatric HCT recipients were prospectively enrolled at Samsung Medical Center, Seoul, Korea during 2009-2011. Patients received vaccines at least one year after HCT according to our study protocol. After blood collection was performed at scheduled time points, serum from each patient was separated within 1 hour and stored at -80°C. ELISA tests to detect anti-PRP IgG antibody and antibodies to Sp serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F were performed at the Center for Vaccine Evaluation and Study, Ewha Medical Research Institute, Seoul, Korea. Results: Ten pediatric HCT recipients ...
Hematopoietic stem cell transplantation (HSCT) is an established therapeutic procedure for several congenital and acquired disorders, both malignant and nonmalignant. Despite the great improvements in HSCT clinical practices over the last few decades, complications, such as graft vs. host disease (GVHD) and sinusoidal obstructive syndrome (SOS), are still largely unpredictable and remain the major causes of morbidity and mortality. Both donor and patient genetic background might influence the success of bone marrow transplantation and could at least partially explain the inter-individual variability in HSCT outcome. This review summarizes some of the recent studies on candidate gene polymorphisms in HSCT, with particular reference to pediatric cohorts. The interest is especially focused on pharmacogenetic variants affecting myeloablative and immunosuppressive drugs, although genetic traits involved in SOS susceptibility and transplant-related mortality are also reviewed.
HB vaccine to prevent viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection ...
CLEVELAND, Feb. 1, 2012 (GLOBE NEWSWIRE) - Athersys, Inc. (Nasdaq:ATHX - News) today announced positive results from its Phase I clinical trial of MultiStem(R), its cell therapy product, administered to individuals undergoing allogeneic hematopoietic stem cell transplants (HSCT) for the treatment of leukemia and related conditions. According to the Center for International Blood and Marrow Transplant Research, there are approximately 25,000 allogeneic HSCT performed annually, globally. The study demonstrated that MultiStem therapy was well tolerated in both the single infusion and repeat infusion arms and also suggested that the therapy may provide benefit to recipients of allogeneic HSCT, such as reducing the incidence and severity of Graft-versus-Host Disease (GvHD) as compared to historical clinical experience. The results are consistent with previous preclinical studies that show that MultiStem provides multiple benefits in HSCT and other transplant models, such as reducing inflammatory ...
The New England journal of medicine, 2001; 345 (25) doi:10.1056/NEJMoa011826. Authors: Petersdorf E W, Hansen J A, Martin P J, Woolfrey A, Malkki M Petersdorf E W, Hansen J A, Martin P J, Woolfrey A, Malkki M, Gooley T, Storer B, Mickelson E, Smith A, Anasetti C et al.(5) Affiliation: Fred Hutchinson Cancer Research Center, United States Sample size: 471 Abstract: BACKGROUND: Successful engraftment of hematopoietic stem cells from unrelated donors is influenced by disparities between the donor and recipient for HLA-A, B, and C alleles. Disparities between HLA sequence polymorphisms that are serologically detectable are termed antigen mismatches, whereas those that can be identified only by DNA-based typing methods are termed allele mismatches. Whether both kinds of polymorphisms are important in transplantation is not known. We tested the hypothesis that allele mismatches that are detectable only at the DNA level are less immunogenic than those that are serologically detectable and thereby are ...
tyrosine kinase is a molecular abnormality that causes chronic myeloid leukemia and Ph+ ALL [15]. Imatinib, the first approved tyrosine kinase inhibitor, plays a major role in the outcomes of Ph+ ALL, as well as in chronic myeloid leukemia. Treatment outcomes, including the OS, EFS, CR, and relapse rate and minimal residual disease of newly diagnosed Ph+ ALL patients are reportedly improved following imatinib-based therapy. Furthermore, many previous studies have reported the favorable effect of imatinib on allogeneic HSCT outcomes. The patients analyzed in these studies usually received imatinib in induction or post-induction therapy before HSCT at 260-340 mg/m2/day for 2 weeks or until HSCT [2324].. In contrast to the aforementioned findings, the overall effect of post-transplant imatinib administration on the outcomes of allogeneic HSCT remains undetermined. Several studies have reported the safety and efficacy of imatinib therapy after allogeneic HSCT. One study reported favorable 5-year OS ...
Objectives: Autologous haematopoietic stem cell transplantation (HSCT) with CD34+ cell selection has recently been used in the treatment of refractory Crohns disease, showing good safety and promising efficacy. We investigated the safety and efficacy of HSCT with unselected peripheral blood stem cells (PBSCs) in moderate-severe refractory Crohns disease.. Patients: Four patients (three male, one female; age range 26-45 years) with active moderate-severe Crohns disease (median Crohns Disease Activity Index (CDAI) 319, range 272-345), refractory or intolerant to multiple drugs including infliximab, were enrolled.. Interventions: Unselected PBSCs were collected after mobilisation with cyclophosphamide (CTX) 1.5 g/m2 and granulocyte-colony stimulating factor (G-CSF) 10 μg/kg. The conditioning regimen included CTX 50 mg/kg on days −5 to −2 and rabbit anti-thymocyte globulin (ATG) 2.5 mg/kg on days −4 to −2.. Main outcome measures: Primary endpoints were toxicity and clinical remission ...
This case series describes 7 patients with severe chronic graft-versus-host disease (cGvHD) associated with bronchiolitis obliterans (BO) after allogeneic hematopoietic stem cell transplantation (HCT) who underwent lung transplantation. About 20% of patients with severe cGVHD develop BO, which portends a poor prognosis. Lung transplantation may be performed for severe refractory BO. In this group, 6 patients underwent bilateral lung transplantation and 1 underwent single lung transplantation. Explanted lung pathology confirmed BO in all patients. The median survival after lung transplantation in this group was 24 months. The authors conclude that lung transplantation is a possible therapeutic option for certain patients with severe therapy-refractory BO.. ...
Azole therapy is widely utilized in hematopoietic stem cell transplant (HCT) recipients for the treatment of aspergillus. Complications of voriconazole treatment related to its elevated fluoride content have been described in adults, including reports of symptomatic skeletal fluorosis. We review fluoride levels, clinical, and laboratory data in five pediatric HCT recipients on long-term voriconazole therapy, all found to have elevated serum fluoride levels. Two patients had toxic fluoride levels, one infant had symptoms of significant pain with movement and radiographs confirmed skeletal fluorosis. Monitoring fluoride levels in children, especially with skeletal symptoms, should be considered in patients on long-term voriconazole. ...
TY - JOUR. T1 - Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. AU - Basak, Grzegorz W.. AU - Jaksic, Ozren. AU - Koristek, Zdenek. AU - Mikala, Gabor. AU - Basic-Kinda, Sandra. AU - Mayer, Jiri. AU - Masszi, Tamas. AU - Giebel, Sebastian. AU - Labar, Boris. AU - Wiktor-Jedrzejczak, Wieslaw. PY - 2011/6/1. Y1 - 2011/6/1. N2 - A proportion of patients with multiple myeloma (MM) who have already undergone autologous stem cell transplantation (autoSCT) might benefit from a further transplantation. For this, they might need to undergo another round of stem cell mobilization. We analyzed retrospectively the outcomes of stem cell mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) in a group of 30 patients who had undergone autoSCT previously, and in 46 other patients. The previously transplanted patients were significantly different from the remaining patients with respect to the ...
I am Associate Professor of Hematology/ Bone Marrow Transplantation in Medical School of University of Patras/ Greece and Clinical Program Director of the Bone Marrow Transplantation and Leukemia Program at Patras University Hospital. I am German Board Certified in Internal Medicine, Hematology and Oncology. I have been working in the field of medical oncology and hematology for ten years in Germany and for the past seven years in Greece. After completing my medical studies in Greece, I moved (1995-2005) to the Dept. of Hematology/Oncology of Freiburg University / Germany (Dir. Prof. R. Mertelsmann), where I completed my PhD Thesis on hematopoietic stem cell biology and engineering, my internal medicine training, my hematology and oncology training and a specialist training in Hematopoietic Stem Cell Transplantation (HSCT). I have been given the Venia Legendi (Assistant Professorship) of the University of Freiburg in 2004. In 2006, I was appointed Assistant Professor at the University of Patras ...
Inherited bone marrow failure (IBMF) syndromes are a heterogeneous group of rare hematological disorders characterized by the impairment of hematopoiesis, which harbor specific clinical presentations and pathogenic mechanisms. Some of these syndromes may progress through clonal evolution, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Most prominent are failures of DNA repair such as Fanconi Anemia and much rarer failure of ribosomal apparatus, e.g., Diamond Blackfan Anemia or...
Background. Respiratory syncytial virus (RSV) can be fatal in immunocompromised patients. Aerosolized ribavirin is used for treatment but it is costly, teratogenic, and inconvenient. We aimed to assess the outcome of oral ribavirin, with or without intravenous immunoglobulin (IVIG) for RSV in immunocompromised patients.. Methods. The medical records of moderate to severely immunocompromised patients with RSV infection in 2011-12 were reviewed. Severely immunocompromised patients were defined as (1) allogenic hematopoietic stem cell transplant (HSCT) patients ,6 months after transplantation or beyond 6 months with ,grade 2 GVHD and (2) lung recipients in the first year post-transplant or beyond one year with augmented immunosuppression. Moderately immunocompromised patients were (1) other solid organ transplant recipients, (2) patients with hematologic malignancies receiving chemotherapy, (3) allogenic HSCT patients ,6 months after HSCT or with GVHD ,grade 2, (4) autologous HSCT patients, and (5) ...
Leukodystrophies (LD) are devastating inherited disorders leading to rapid neurological deterioration and premature death. Hematopoietic stem cell transplantation (HSCT) can halt disease progression for selected LD. Cord blood is a common donor source for transplantation of these patients because it is rapidly available and can be used without full HLA matching. However, precise recommendations allowing care providers to identify patients who benefit from HSCT are lacking. In this study, we define risk factors and describe the early and late outcomes of 169 patients with globoid cell leukodystrophy, X-linked adrenoleukodystrophy, and metachromatic leukodystrophy undergoing cord blood transplantation (CBT) at an European Society for Blood and Marrow Transplantation center or at Duke University Medical Center from 1996 to 2013. Factors associated with higher overall survival (OS) included presymptomatic status (77% vs 49%;P= .006), well-matched (≤1 HLA mismatch) CB units (71% vs 54%;P= .009), ...
Purpose: : To describe the outcome of penetrating keratoplasty (PKP) in patients who had previously undergone cultivated limbal stem cell transplantation. Methods: : Medical records of patients with limbal stem cell deficiency who underwent PKP after cultivated limbal stem cell transplantation were reviewed for demographics, primary etiology, type of surgical procedure, best corrected visual acuity, ocular surface conditions and complications. Results: : Thirty-eight patients with limbal stem cell deficiency underwent PKP at a mean interval of 23.5 months (range: 6-92 months) following cultivated limbal stem cell transplantation. Twenty-one patients (55.3%) underwent PKP, 17 patients (44.7%) PKP combined with cataract extraction. Preoperative best-corrected visual acuity was less than 1/10 in 29 of the 38 eyes (76.3%). At a mean follow-up of 27.5 months (range: 1-92 months) after PKP, the best-corrected visual acuity improved in 33 patients (86.8%), worsened in 3 (7.9%) and remained unchanged in ...

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation...Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation...

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation ... BED safely and effectively mobilizes hematopoietic stem cells.Bone Marrow Transplantation advance online publication, 23 May ... successfully yielded stem cells (median of 21.60 × 10(6)/kg of body weight; range 9.24-55.5 × 10(6)/kg), and 88% required a ... to evaluate bendamustines efficacy and safety as a stem cell mobilizing agent. Patients received bendamustine (120 mg/m(2) IV ...
more infohttps://scicurve.com/paper/27214069

Hypomethylating agents are effective in myelodysplastic syndrome | Cancer BiologyHypomethylating agents are effective in myelodysplastic syndrome | Cancer Biology

MDS develops as the consequence of a series of genetic changes in a hematopoietic stem cell. These changes alter normal ... disease are considered for front-line chemotherapy approaches followed perhaps by allogeneic stem cell transplantation. ... Non-proliferating cells are relatively insensitive to decitabine.. Biological mechanism of action of azacitidine (AZA) and ... In rapidly dividing cells, the cytotoxicity of decitabine may also be attributed to the formation of covalent adducts between ...
more infohttps://blogs.shu.edu/cancer/2016/09/28/hypomethylating-agents-are-effective-in-myelodysplastic-syndrome/

Hematopoietic stem cell transplantation - WikipediaHematopoietic stem cell transplantation - Wikipedia

Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... See also: List of conditions treated with hematopoietic stem cell transplantation. Indications[edit]. Indications for stem cell ... Stem cell transplantation was pioneered using bone-marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research ... Cutler C, Antin JH (2001). "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. ...
more infohttps://en.wikipedia.org/wiki/Bone_Marrow_Transplant

What is hematopoietic stem cell transplantation?What is hematopoietic stem cell transplantation?

This article explores the process of transplantation, how to choose a donor, and the risks involved with such a procedure. Read ... Hematopoietic stem cell transplantation is approved for use in treating some types of cancer and is an experimental treatment ... While the therapy is a form of stem cell transplantation, the stem cells are not the main part of the story. In fact, the key ... Hematopoietic stem cell transplantation was first used as a treatment for some types of cancer but is now widely used as a ...
more infohttps://www.medicalnewstoday.com/articles/318091.php?iacp

Hematopoietic stem cell transplantation - WikipediaHematopoietic stem cell transplantation - Wikipedia

Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... See also: List of conditions treated with hematopoietic stem cell transplantation. IndicationsEdit. Indications for stem cell ... Stem cell transplantation was pioneered using bone-marrow-derived stem cells by a team at the Fred Hutchinson Cancer Research ... Cutler C, Antin JH (2001). "Peripheral blood stem cells for allogeneic transplantation: a review". Stem Cells. 19 (2): 108-17. ...
more infohttps://en.m.wikipedia.org/wiki/Bone_marrow_transplant

Hematopoietic stem cell transplantation | SCCAAHematopoietic stem cell transplantation | SCCAA

Before transplantation, patients receive intensive myeloablative chemoradiotherapy followed by stem cell ... More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each year for the treatment of lymphoma, ... Hematopoietic stem cell transplantation Eleftheria Hatzimichael1, Mark Tuthill21Department of Haematology, Medical School of ... transplantation procedures, and potential complications.. Keywords: hematopoietic stem cell transplantation, complications. ...
more infohttps://www.dovepress.com/hematopoietic-stem-cell-transplantation-a5132

Aspergillus Thyroiditis after Allogeneic Hematopoietic Stem Cell TransplantationAspergillus Thyroiditis after Allogeneic Hematopoietic Stem Cell Transplantation

... Pinar Ataca,1 Erden Atilla,1 Pelin Saracoglu, ... "Aspergillus Thyroiditis after Allogeneic Hematopoietic Stem Cell Transplantation," Case Reports in Hematology, vol. 2015, ...
more infohttps://www.hindawi.com/journals/crihem/2015/537187/cta/

Role of HLA in Hematopoietic Stem Cell TransplantationRole of HLA in Hematopoietic Stem Cell Transplantation

Meerim Park and Jong Jin Seo, "Role of HLA in Hematopoietic Stem Cell Transplantation," Bone Marrow Research, vol. 2012, ... Role of HLA in Hematopoietic Stem Cell Transplantation. Meerim Park1 and Jong Jin Seo2 ...
more infohttps://www.hindawi.com/journals/bmr/2012/680841/cta/

hematopoietic stem cell transplantation | Haematologicahematopoietic stem cell transplantation | Haematologica

T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation ... Allogeneic stem cell transplantation in paroxysmal nocturnal hemoglobinuria Régis Peffault de Latour, Hubert Schrezenmeier, ...
more infohttp://www.haematologica.org/keyword/hematopoietic-stem-cell-transplantation-1

Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - 2nd EditionImmune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - 2nd Edition

Purchase Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - 2nd Edition. Print Book & E-Book. ISBN ... Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation 2nd Edition. Models in Discovery and Translation. 0 star ... Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation: Models in Discovery and Translation, Second Edition once ... Robert Zeiser serves as Full Professor of Medicine at the Department of Hematology, Oncology and Stem Cell Transplantation ...
more infohttps://www.elsevier.com/books/immune-biology-of-allogeneic-hematopoietic-stem-cell-transplantation/socie/978-0-12-812630-1

Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma in India | SpringerLinkAutologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma in India | SpringerLink

Kumar L, Boya RR, Pai R et al (2016) Autologous stem cell transplantation for multiple myeloma: long-term results. Natl Med J ... Naithani R, Dayal N, Dixit G (2017) Single versus dual platform analysis for hematopoietic stem cell enumeration using ISHAGE ... Malhotra P, Yanamandra U, Khadwal A et al (2017) Autologous stem cell transplantation for multiple myeloma: single centre ... Prinja S, Kaur G, Malhotra P et al (2017) Cost-effectiveness of autologous stem cell treatment as compared to conventional ...
more infohttps://link.springer.com/article/10.1007/s12288-018-0951-z

Complications of Bone Marrow or Hematopoietic Stem Cell TransplantationComplications of Bone Marrow or Hematopoietic Stem Cell Transplantation

... Complications of Bone Marrow or Hematopoietic Stem Cell ... Complications of bone marrow transplantation/ hematopoietic stem cell transplantation include:. Complications due to ... Complications of Bone Marrow Transplantation. Complications of Bone Marrow or Hematopoietic stem cell transplantation include ... Luxury Furniture Exhausts Budget of Japan Stem Cell Body. * Transplantation With Human Placental Stem Cells Improves Diabetes ...
more infohttps://www.medindia.net/patients/patientinfo/bone-marrow-transplantation-complications.htm

Hematopoietic Stem Cell Transplantation | Medical City DallasHematopoietic Stem Cell Transplantation | Medical City Dallas

Learn more about Hematopoietic Stem Cell Transplantation at Medical City Dallas DefinitionReasons for ProcedurePossible ... Stem cells produce red blood cells, white blood cells, and platelets. In some cases, stem cells in your bone marrow may not be ... If this happens, you will need new stem cells.. It may take about a month for the donor stem cells in the bone marrow to begin ... www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant/stem-cell-fact-sheet. Updated August 12, 2013. Accessed ...
more infohttps://medicalcityhospital.com/hl/?/14774/stem-cell-transplant&com.dotmarketing.htmlpage.language=1

Erythrocytosis after allogeneic hematopoietic stem cell transplantationErythrocytosis after allogeneic hematopoietic stem cell transplantation

Yutaro Hino; Noriko Doki; Shuhei Kurosawa; Keita Yamamoto; Masahiro Sakaguchi; Kaito Harada; Shuntaro Ikegawa; Naoki Shingai; Kenichiro Hattori; Yasushi Senoo; Aiko Igarashi; Yuho Najima; Takeshi Kobayashi; Kazuhiko Kakihana; Hisashi Sakamaki; Kazuteru Ohashi + Author Information ...
more infohttps://insights.ovid.com/pubmed?PMID=28247439

Hematopoietic Stem Cell Transplantation - The Clare ChampionHematopoietic Stem Cell Transplantation - The Clare Champion

Hematopoietic Stem Cell Transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ... HSCT involves the intravenous (IV) infusion of autologous or allogeneic stem cells to re-establish hematopoietic function in ... Home » Tag Archives: Hematopoietic Stem Cell Transplantation. Tag Archives: Hematopoietic Stem Cell Transplantation ... Sarah McInerney (40) has obtained chemotherapy and a stem cell transplant, which is not available in Ireland to treat ...
more infohttp://clarechampion.ie/tag/hematopoietic-stem-cell-transplantation/

Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review.  - PubMed - NCBICytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. - PubMed - NCBI

Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review.. Ariza-Heredia EJ1, Nesher L, Chemaly RF ... Cytomegalovirus (CMV) infection remains a significant complication after hematopoietic stem cell transplantation (HSCT) and may ... have a deleterious impact on the overall outcome after transplantation. In addition to the direct effects of CMV infection, ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/24041869

Chronic granulomatous disease: overview and hematopoietic stem cell transplantation.  - PubMed - NCBIChronic granulomatous disease: overview and hematopoietic stem cell transplantation. - PubMed - NCBI

Chronic granulomatous disease: overview and hematopoietic stem cell transplantation.. Kang EM1, Marciano BE, DeRavin S, ... The difficulty in considering high-risk yet curative treatments, such as allogeneic bone marrow transplantation, lies in the ... Therefore, with recent developments and improvements, bone marrow transplantation, previously considered an experimental or ... unpredictable courses of both CGD and bone marrow transplantation in different patients. Some patients with CGD can have ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/21497887?dopt=Abstract

Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma | LeukemiaAllogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma | Leukemia

Therefore, the aim of this study was to assess the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) ... These data suggest that better control of GS prior to allo-HSCT is crucial to improve the outcome of transplantation for those ... A total of 44 patients (8.7%) had GS before transplantation. Patients with GS achieved comparable survival to those without GS ... Allogeneic hematopoietic stem cell transplantation for adult AML patients with granulocytic sarcoma. *H Shimizu. 1. ,12. , ...
more infohttps://www.nature.com/articles/leu2012156?error=cookies_not_supported&code=c1a3c897-5879-4a7e-aea5-7f9d80df1ad1

Hematopoietic Stem Cell Transplantation in Type 1 Diabetes MellitusHematopoietic Stem Cell Transplantation in Type 1 Diabetes Mellitus

... clinicaltrials.gov The purpose of this study is to determine if autologous nonmyeloablative hematopoietic stem cell ... Hematopoietic Stem Cell Transplantation. Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals ... Stem Cell Transplantation. The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, ... to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION ...
more infohttps://www.bioportfolio.com/resources/trial/65089/Hematopoietic-Stem-Cell-Transplantation-in-Type-1-Diabetes-Mellitus.html

Predictability of hematopoietic stem cell transplantation rates | HaematologicaPredictability of hematopoietic stem cell transplantation rates | Haematologica

2003) in Hematopoietic cell transplantation, Uses and growth of hematopoetic cell transplantation, eds Forman SJ, Blume KG, ... Predictability of hematopoietic stem cell transplantation rates. Alois Gratwohl, Helen Baldomero, Alvin Schwendener, Michael ... Predictability of hematopoietic stem cell transplantation rates. Alois Gratwohl, Helen Baldomero, Alvin Schwendener, Michael ... Predictability of hematopoietic stem cell transplantation rates Message Subject (Your Name) has forwarded a page to you from ...
more infohttp://www.haematologica.org/content/92/12/1679

Hematopoietic Stem Cell Transplantation | Grand Strand HealthHematopoietic Stem Cell Transplantation | Grand Strand Health

Learn more about Hematopoietic Stem Cell Transplantation at Grand Strand Medical Center DefinitionReasons for ProcedurePossible ... Stem cells produce red blood cells, white blood cells, and platelets. In some cases, stem cells in your bone marrow may not be ... If this happens, you will need new stem cells.. It may take about a month for the donor stem cells in the bone marrow to begin ... www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant/stem-cell-fact-sheet. Updated August 12, 2013. Accessed ...
more infohttps://grandstrandmed.com/hl/?/14774/Bone-Marrow-Transplantation&com.dotmarketing.htmlpage.language=1

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma - Tabular View - ClinicalTrials.govAllogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma - Tabular View - ClinicalTrials.gov

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Official Title ICMJE A Phase II Study of Allogeneic ... Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma (Flu-Mel-Vel). This study is ongoing, but not ... Hematopoietic Stem Cell Transplantation for Multiple Myeloma Using a Conditioning Regimen of Fludarabine, Melphalan, and ... with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy ...
more infohttps://clinicaltrials.gov/ct2/show/record/NCT01453101

Depleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation | ScienceDepleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation | Science

Depleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation. By Yuki Taya, Yasunori Ota, ... Depleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation. By Yuki Taya, Yasunori Ota, ... Depleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation Message Subject. (Your Name) ... 1Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, ...
more infohttp://science.sciencemag.org/content/early/2016/10/19/science.aag3145/tab-article-info

Pregnancy after allogeneic hematopoietic stem cell transplantation in  | IMCRJPregnancy after allogeneic hematopoietic stem cell transplantation in | IMCRJ

... hematopoietic stem cell transplantation). We describe the case of a term pregnant woman with FA who was treated with BMT 2 ... However, there are reports of successful pregnancy in Fanconi patients after bone marrow transplantation (BMT, ... Keywords: Fanconi anemia, bone marrow transplantation, pregnancy, cesarean section, spinal anesthesia ... Pregnancy after allogeneic hematopoietic stem cell transplantation in a Fanconi anemia patient Simin Atashkhoei, Solmaz Fakhari ...
more infohttps://www.dovepress.com/pregnancy-after-allogeneic-hematopoietic-stem-cell-transplantation-in--peer-reviewed-article-IMCRJ
  • Thus, means to enhance numbers and/or potency of collected cells and their engrafting capability through ex-vivo and/or in-vivo maneuvers would likely enhance the efficacy and applicability of CB transplantation. (stembook.org)
  • To test this hypothesis in preclinical settings, we have previously developed several experimental models of GVHD using TK+ T-cells in mice. (bioportfolio.com)
  • Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation: Models in Discovery and Translation, Second Edition once again provides clinical and scientific researchers with a deep understanding of the current research in this field and the implications for translational practice. (elsevier.com)
  • 1 Division of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan. (sciencemag.org)
  • 3 Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Lorry I. Lokey Stem Cell Research Building, 265 Campus Drive, Stanford, CA 94305-5461, USA. (sciencemag.org)
  • Such efforts require a deeper understanding of the cell biology of HSC and HPC, the microenvironment that nurtures these cells, and greater mechanistic insight into cell surface receptors and intracellular signaling pathways regulating HSC/HPC function. (stembook.org)
  • Hematopoietic stem cell transplantation was first used as a treatment for some types of cancer but is now widely used as a therapy for various autoimmune diseases. (medicalnewstoday.com)
  • Stem cell treatments are still in the experimental stages for treating autoimmune diseases. (medicalnewstoday.com)
  • Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. (nih.gov)
  • In case of previous std-DLI received, the DLI-TK cell dose is adjusted to be below or equal to the maximal cell dose previously received in std-DLI. (bioportfolio.com)
  • Hematopoietic stem cell transplantation may be used to treat a number of conditions both congenital and acquired. (wikipedia.org)
  • Since the establishment of the autoimmune etiology of type 1 DM in the late 1970s, many clinical trials analyzing the effects of different types of immune interventions demonstrated that beta-cell preservation is an achievable target in different degrees. (bioportfolio.com)
  • We have developed a strategy of alloreactive T-cell depletion, using T-cells expressing the Herpes simplex thymidine kinase (TK) suicide gene combined with a ganciclovir (GCV) treatment. (bioportfolio.com)